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Abstract 
The two most abundant phytochemical compounds in cannabis are cannabidiol (CBD) and ∆9-
tetrahydrocannabinol (THC). THC is the primary psychoactive component of cannabis and is a 
partial CB1 receptor (CB1R) agonist. THC is believed to be responsible for the motivational and 
dependence-producing effects of cannabis and causes psychotomimetic and affective processing 
disturbances. Conversely, CBD, is non-psychoactive, acts as a 5-HT1A receptor agonist, 
antagonizes CB1Rs, and possesses both anti-psychotic and anxiolytic properties. The neural 
substrate believed to be responsible for many of the effects of cannabis is the dopaminergic, 
mesolimbic reward pathway which is responsible for the regulation of cognition and emotion. 
Specifically, the shell region of the nucleus accumbens (NASh) and the ventral tegmental area 
(VTA) are important brain areas involved in motivation, reward, aversion, and fear-related 
behavioural processing. Using a combination of behavioural, electrophysiology and molecular 
techniques, the first chapter evaluates the effects of direct infusions of CBD into the NASh. 
Intra-NASh CBD blocked the formation of fear memory through a 5-HT1A-dependent 
mechanism by functionally modulating the activity of neuronal activity dynamics directly in the 
VTA. In the second chapter, we examined the effects of THC in either the anterior NASh 
(aNASh), known as the “hedonic hotspot”, or posterior NASh, known to be involved in aversion. 
We demonstrate that aNASh THC produced rewarding behavioural effects and modulated 
reward salience through a µ-opioid-receptor-dependent mechanism, whereas THC in the pNASh 
produced aversive behavioural effects through a -opioid-receptor-dependent mechanism. ICV 
infusions of THC caused aNASh MSN activity to decrease and increased the power of ɣ-
oscillations on the local field potential but caused pNASh increased MSN activity and decreased 
the power of ɣ-oscillations on the local field potential. Finally, in the third chapter, we provide a 
characterization of how THC differentially regulates fear-related memory formation and 
cognitive processing via distinct Akt-dependent vs. GSK3-dependent signaling pathways, in the 
aNASh vs. pNASh, respectively. Together, these data provide a novel neuronal, molecular, 
behavioural and anatomical characterization of the effects of CBD and THC directly within the 
mesolimbic circuitry and reveals critical new insights into the mechanisms by which THC and 
CBD regulate affective and cognitive behaviours. 
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CHAPTER 1 
1 General Introduction  
 2 
1.1  CANNABIS USE AND PHYTOCHEMICAL PROPERTIES 
Cannabis is the most widely used illicit drug in the world, with 182 million users globally in 
2016 (United Nations Office on Drugs and Crime, 2018). As several countries prepare for full 
legalization of recreational use, rates of cannabis consumption are likely to increase. Heralding 
legalization is a widespread attitude shift that cannabis use is harmless. The effects of cannabis 
on the body and brain, however, are complex and still poorly understood. Previous research has 
established that, like most other drugs of abuse, cannabis is addictive (Maldonado, Berrendero, 
Ozaita, & Robledo, 2011) and can cause users to seek increasing amounts of the drug despite 
negative consequences. Additionally, heavy cannabis use, particularly during periods of 
adolescent brain development, has been demonstrated to increase the likelihood of developing 
schizophrenia (Arseneault, 2002). Conversely, cannabis is frequently used to treat pain (Allan et 
al., 2018; Ware et al., 2010), and some recent evidence suggests it may also be beneficial for 
PTSD and schizophrenia (Blessing, Steenkamp, Manzanares, & Marmar, 2015; Bonn-Miller, 
Vujanovic, & Drescher, 2011; Haney & Evins, 2016; Iseger & Bossong, 2015; Schubart et al., 
2014; Zuardi, Crippa, Hallak, Moreira, & Guimaraes, 2006). 
 
One of the biggest challenges to studying the effects of cannabis is that the plant is known to 
contain over 100 distinct phytochemicals (Radwan et al., 2009), each with their own unique 
pharmacology. Thus, to fully understand the potential therapeutic or detrimental effects of 
cannabis on mental health, it is crucial to characterize the neuropharmacological, anatomical and 
neurophysiological effects of each individual compound. Nevertheless, the two most prevalent 
and best characterized phytochemicals in cannabis are ∆9-tetrahydrocannabinol (THC), the 
primary psychoactive compound and the source of the dependence-producing properties, and 
cannabidiol (CBD), the most abundant, but non-psychoactive, compound. THC is also believed 
to be responsible for the pro-psychotic, anxiogenic and aversive properties of cannabis (Childs, 
Lutz, & de Wit, 2017; Freeman et al., 2015; Renard, et al., 2017; Schramm-Sapyta et al., 2007). 
CBD, however, is known to possess anti-psychotic (Zuardi et al., 2006) and anxiolytic (Campos 
et al., 2013; Crippa et al., 2011) properties, and can modulate the processing of associative fear 
memories (Das et al., 2013; Norris et al., 2016). CBD also modulates or reverses some of the 
negative side effects of THC administration. For example, co-administration of CBD with THC, 
inhibits THC-induced paranoia and memory loss (Englund et al., 2013). In addition, our 
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laboratory has shown previously that THC and CBD can produce diametrically opposing effects 
on dopamine (DA) neuronal activity states and on the activation states of several molecular 
signaling pathways linked to neuropsychiatric disorders, such as glycogen synthase kinase-3 
(GSK3), Protein Kinase B (Akt), mammalian target or rapamycin (mTOR) and p70-S-6-Kinase 
(p70S6K), with THC inhibiting and CBD activating these pathways in distinct 
mesocorticolimbic brain regions, respectively (Renard et al., 2016, 2017). Thus, despite the 
structural similarity and common botanical origins of these phytocannabinoids, they are capable 
of exerting opposing effects on many neuronal and molecular substrates linked to 
neuropsychiatric disorders, such as schizophrenia, anxiety, depression and addiction. 
 
The underlying pharmacological mechanisms of THC and CBD are also distinct. THC exerts 
partial agonist activity on two receptors in the endocannabinoid (eCB) system, the cannabinoid1 
receptor (CB1R) and the cannabinoid2 receptor (CB2R) (Pertwee, 2008). Many of the effects of 
THC, however, also rely on interactions with other neurotransmitter systems. For example, 
reward from low doses of THC is not present in µ-opioid knockout rats and aversion from high 
doses of THC is not present in -opioid receptors knockout rats (Ghozland et al., 2002).  
 
CBD, however, has much more diverse effects. It is an agonist of the serotonin receptor 5-HT1A 
(Campos & Guimarães, 2008; Russo, Burnett, Hall, & Parker, 2005), an agonist of PPAR 
(O’Sullivan, 2016), a negative allosteric modulator of CB1 (Tham et al., 2018), and it prevents 
the degradation of endogenous cannabinoids through the inhibition of the enzyme fatty acid 
amide hydrolase (FAAH) (Leweke et al., 2012). Increased 5-HT1A transmission is believed to be 
the key determinant in response to serotonin reuptake inhibitors when treating depression (Blier 
& Abbott, 2001). Additionally, 5-HT1A receptor agonists possess anxiolytic properties (File & 
Gonzalez, 1996) and 5-HT1A knockout mice show increased anxiety that cannot be rescued by 
antidepressant treatment (Toth, 2003). Moreover, antipsychotic drugs that stimulate 5-HT1A 
receptors induce dopamine release in the mesolimbic reward pathway, which likely plays a role 
in their effectiveness at treating schizophrenia (Bantick, De Vries, & Grasby, 2005; Bantick, 
Deakin, & Grasby, 2001; Li, Ichikawa, Dai, & Meltzer, 2004; Rollema, Lu, Schmidt, Sprouse, & 
Zorn, 2000). Taken together, this evidence suggests that the activity of CBD at 5-HT1A receptors 
might be the primary mechanism responsible for the putative therapeutic effects of cannabis on 
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psychiatric illness. Nevertheless, the diverse and wide range of effects of THC and CBD 
necessitates in depth investigations into their influence in the brain. 
 
1.2  THE ENDOCANNABINOID SYSTEM 
The biological system that most cannabinoids interact with is known as the endocannabinoid 
(eCB) system and, in mammalian species, is crucial to the normal function of the organism, both 
centrally and peripherally. Indeed, eCB receptors and ligands are present everywhere in the body 
and serve primarily as neuromodulators of other neurotransmitter systems. CB2Rs were 
originally thought to only be expressed in the periphery, while this remains their primary locus, 
some are present on microglia in the central nervous system (CNS) (Cabral, Raborn, Griffin, 
Dennis, & Marciano-Cabral, 2008). CB1Rs, however, were originally thought to only be 
expressed in the CNS but more recent evidence has demonstrated they are also expressed 
throughout the body (Herkenham et al., 1990; Pagotto, Marsicano, Cota, Lutz, & Pasquali, 
2006). Both CBRs are G-protein coupled receptors and respond to a diverse range of exogenous 
and endogenous cannabinoids. Activation of these receptors typically blocks adenyl cyclase and 
decreases levels of cyclic adenosine monophosphate (cAMP). Changes in cAMP is linked to 
dozens of different molecular processes within the neuron that serve diverse functions.  
The two primary eCBs in the brain are anandamide (AEA) and 2-arachidonoylglycerol (2-AG), 
which both act as retrograde messengers at the synaptic cleft. They are synthesized and released 
by the postsynaptic neuron and activate CB1Rs on the presynaptic terminal, modulating the 
release of other neurotransmitters, regulating neural excitability, and stimulating the glia-neuron 
interaction (Ohno-Shosaku, Tanimura, Hashimotodani, & Kano, 2012). CB1Rs are associated 
with social behaviour (Litvin, Phan, Hill, Pfaff, & McEwen, 2013; Wei, Allsop, Tye, & Piomelli, 
2017), reward (Sanchis-Segura, Cline, Marsicano, Lutz, & Spanagel, 2004), learning (Bergado 
Acosta, Schneider, & Fendt, 2017), emotional behaviour (Rubino et al., 2008; Ruehle, Rey, 
Remmers, & Lutz, 2012), memory (Marsicano & Lafenêtre, 2009; Morena & Campolongo, 
2014) and sensorimotor gating (Ortega-Álvaro et al., 2015). THC has substantial binding affinity 
to both CBRs, but CB1Rs appear to be responsible for the neuropsychiatric effects of cannabis 
consumption.  
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Anatomically, CB1Rs are present throughout the brain but are not uniformly distributed. There 
are high concentrations of the receptor in the structures that compose the mesolimbic reward 
pathway, which is responsible for appetitive processing, cognition and memory (Tsou, Brown, 
Sañudo-Peña, Mackie, & Walker, 1998). For example, activation of CB1Rs in the nucleus 
accumbens (NAc), an important area within the mesolimbic pathway, impairs contextual fear 
learning (Pedroza-Llinás, Méndez-Díaz, Ruiz-Contreras, & Prospéro-García, 2013), and, 
conversely, activating CB1Rs in the medial prefrontal cortex (mPFC) potentiates the learning of 
an olfactory associative fear memory (Laviolette & Grace, 2006). Additionally, CB1R signaling 
in the mesolimbic pathway has been demonstrated to play a significant role in drug reward. For 
example, amphetamine-induced dopamine release in the shell region of the NAc (NASh) was 
shown to be dependent on CB1R activation (Kleijn et al., 2012) and blockade of CB1Rs in the 
NAc was shown to potentiate morphine sensitization behaviours (Haghparast, Azizi, 
Hassanpour-Ezatti, Khorrami, & Naderi, 2009). 
 
1.3  THE MESOLIMBIC REWARD PATHWAY 
The mesolimbic reward pathway is a dopaminergic (DAergic) circuit in the brain responsible for 
motivation, emotion, cognition and memory (Wise, 2004). It consists of the A10 DAergic 
neurons which originate in the ventral tegmental area (VTA) and connect to areas in the striatum 
and forebrain such as, the NAc, the mPFC and, the amygdala (Grace, Floresco, Goto, & Lodge, 
2007; Ikemoto, 2007). Previous research has implicated DA signalling in the mesolimbic 
pathway in reward learning (FitzGerald, Dolan, & Friston, 2015); fear learning and memory 
(Fadok, Darvas, Dickerson, & Palmiter, 2010; Pignatelli et al., 2017); and social behaviour 
(Manduca et al., 2016). A simplified diagram of the mesolimbic reward pathway can be seen in 
Figure 1.1. 
 
Extensive evidence has demonstrated substantial functional interactions between the DA and 
eCB systems. For example, CB1Rs and DA receptors are frequently co-expressed on neurons in 
the forebrain, indicating substantial crosstalk between the neurotransmitter systems (Hermann, 
Marsicano, & Lutz, 2002). Additionally, the eCB system acts as a modulator of afferent inputs to 
dopamine neurons and regulates DA neurotransmission (Covey, Mateo, Sulzer, Cheer, & 
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Lovinger, 2017). Furthermore, DA/ eCB interaction is vital for proper decision-making, as eCBs 
regulate inhibitory and excitatory input into the mesolimbic pathway (Hernandez & Cheer, 
2015). The effects of administration of exogenous cannabinoids also suggests substantial 
interaction between the eCB and DA systems. For example, acute administration of exogenous 
cannabinoids, such as THC, causes strong DA efflux, while chronic THC administration is 
associated with the blunting of DA transmission (van de Giessen et al., 2016). Taken together, 
the evidence strongly indicates that the eCB systems plays a significant role in regulating 
dopamine signaling in the brain. 
 
1.3.1  The Nucleus Accumbens 
The NAc serves as a key integratory area in the mesolimbic pathway. It receives and 
consolidates information from the VTA, the mPFC and the amygdala. Traditionally, the NAc 
was seen as the brain’s primary “reward centre” but subsequent research demonstrated it also 
plays a complex role in decision-making and motivational salience processing. Likewise, the 
NAc plays a significant role in drug reward and addiction-related phenomena (Quintero, 2013; 
Ren et al., 2013), including mediating the rewarding properties of THC (Zangen, Solinas, 
Ikemoto, Goldberg, & Wise, 2006). However, NAc activity is also required for processing 
aversion-related information (Al-Hasani et al., 2015; Qi et al., 2016) and for processing long 
term memories of associative fear learning (Fadok et al., 2010). In addition, the NAc processes 
appetitive information from other areas in the mesolimbic pathway and changes the likelihood, 
efficiency and vigor of goal orientated behaviours. For example, the NAc does not directly 
control food motivation but does mediate approach behaviour, sustained attention, effort, and 
task learning (Hernandez, Sadeghian, & Kelley, 2002; Salamone, Correa, Farrar, & Mingote, 
2007; Salamone & Correa, 2012). Essentially, the NAc motivates individuals toward stimuli that 
result in positive or rewarding outcomes and away from stimuli that result in negative or aversive 
outcomes. Additionally, CB1Rs have been previously demonstrated to play a significant role in 
NAc function. For example, CB1 knockout mice lack morphine induced NAc dopamine release 
(Mascia et al., 1999) but administration of a synthetic CB1 agonist increases NAc dopamine 
release (Sperlágh, Windisch, Andó, & Sylvester Vizi, 2009).  
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Anatomically, the NAc is divided into two distinct areas: the shell (NASh) and the core (NACo). 
The NACo encodes motor information related to reward to facilitate the acquisition of the reward 
and serves as a limbic-motor interface (Mannella, Gurney, & Baldassarre, 2013; Nestler, Hyman, 
Holtzman, & Malenka, 2015). The NASh, however, is believed to be involved in the affective 
and cognitive aspects of reward and aversion-related processing. For example, the NASh is 
responsible for “like” and “dislike” reactions and motivational salience, the form of attention that 
motivates the individual towards or away from a stimulus (Floresco, 2015; Ikemoto & Panksepp, 
1999; Reynolds & Berridge, 2002; Saddoris, Cacciapaglia, Wightman, & Carelli, 2015). The 
shell also plays a much larger role in drug reward and addiction (Crofton et al., 2017; Gaetano Di 
Chiara et al., 2004). Importantly, within the shell itself, recent evidence has demonstrated 
anatomically and functionally distinct sub-regions. For example, the anterior pole of the NASh 
has been characterized as a “hedonic hotspot” because localized pharmacological stimulation of 
the structure with eCBs or select opioid agonists, creates potent rewarding effects. The functional 
division within the structure is believed to be caused by differential concentrations of specific 
opioid receptor subtypes, specifically, the ‘mu’ receptor and the ‘kappa’ receptor subtypes, 
which are independently responsible for signaling rewarding or aversive motivational signals in 
the mesolimbic circuitry, respectively (Peciña & Berridge, 2000; Smith & Berridge, 2007).  
 
Despite evidence for these regional differences in terms of affective processing in the anterior vs. 
posterior shell regions, little is known regarding how specific cannabinoids, such as THC, might 
differentially impact these striatal sub-regions in terms of reward or aversion processing. These 
functional differences are the focus of the studies described in chapters 3 and 4 of this thesis. At 
a cellular level, the NA is mainly composed of the GABAergic inhibitory medium spiny neurons 
(MSNs). MSNs are primarily divided into two subpopulations: cells primarily expressing D1 DA 
receptors and cells primarily expressing D2 receptors. Traditionally, D1 MSNs were thought to 
mediate reward and positive reinforcement and D2 MSNs were believed to mediate aversion and 
negative reinforcement (Kravitz & Kreitzer, 2012; Volman et al., 2013). More recent evidence, 
however, has suggested that this dichotomy does not apply to all reward related behaviours 
(Kupchik et al., 2015; Soares-Cunha, Coimbra, David-Pereira, et al., 2016). For example, 
activation of D2 expressing neurons in the NA increased motivation, suggesting that both 
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subpopulations are important for motivational salience (Soares-Cunha, Coimbra, David-Pereira, 
et al., 2016).  
 
1.3.2  The Ventral Tegmental Area 
The VTA is a structure in the midbrain that acts as the main site for DAergic neurons and plays a 
central role in reward and goal-oriented behaviours. The VTA is one of the primary sites acted 
on by drugs of abuse, including THC (Zangen et al., 2006), and is required for the acquisition 
and expression of many drug-related behaviours (Oliva & Wanat, 2016). Previous evidence has 
demonstrated that the VTA is also involved in conditioned fear responses, indicating that the 
structure is involved in processing negative or aversive associations as well (N. A. Chen et al., 
2016; Matulewicz, Orzeł-Gryglewska, Braszka, Zawistowski, & Jurkowlaniec, 2015; Oliveira, 
Reimer, & Brandão, 2009). Although the actions of the DA neurons in the VTA are the best 
characterized in terms of motivational processing, the VTA also contains opiate receptors (ORs), 
CB1Rs and GABA receptors, localized on both DAergic and GABAergic neuronal populations. 
Anatomically, the VTA is heavily connected with other areas of the mesocorticolimbic system 
and sends afferent connections to the mPFC, BLA and NAc. The NAc also sends GABAergic 
projections back into the VTA, creating a circuit loop that enables both areas to affect the 
neuronal activity states in the other. The VTA/NAc circuit plays a key role in drug reward 
(Ishikawa et al., 2013; Owesson-White et al., 2009) and addiction (Britt & Bonci, 2013; Stuber, 
Britt, & Bonci, 2012). The specific influence of this circuit on associative fear memory 
processing is discussed further in Chapter 2. 
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Figure 1.1 A proposed simplified version of the mesolimbic circuit. A diagram demonstrating 
the highly interconnected nature of the mesolimbic circuit, including the unique connections 
between the hedonic hotspots in the NASh and the ventral pallidum 
 
1.4  MOLECULAR SIGNALLING PATHWAYS ASSOCIATED WITH THE 
EFFECTS OF PHYTOCANNABINOIDS 
Molecular signalling cascades within neurons are responsible for the basic functions governing 
the activity of the cell, including production and phosphorylation of specific proteins. These 
pathways can be affected by exogenous compounds, including cannabinoids, in a variety of 
ways. Signalling proteins act in a complex and highly interconnected manner referred to as an 
‘interactome’. The highly interconnected nature of many cellular signalling pathways can make 
the effects of individual molecules difficult to characterize, but recent studies have elucidated the 
role of many proteins in neuronal activity, specifically as they relate to neuropsychiatric 
disorders and their symptoms.  
 
For example, the Wingless/ Integrated (Wnt) signalling pathways are signal transduction 
mechanisms that pass signals into a cell from a variety of cell surface receptors. Three distinct 
Wnt pathways have currently been discovered: canonical Wnt, which causes the accumulation of 
-catenin in the cytoplasm and eventual translocation into the nucleus to alter transcription; the 
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Wnt/ Jun N-terminal kinase (JNK) pathway, which plays a role in cell morphology; and the 
Wnt/calcium pathway, which regulates the levels of calcium inside the cell (Rao & Kühl, 2010). 
Dysfunction of the Wnt pathways has been linked to numerous psychiatric illnesses such as 
schizophrenia, bipolar disorder and autism (Mulligan & Cheyette, 2016). Moreover, blocking 
glycogen synthase kinase 3 (GSK3), an important molecule in Wnt signaling, directly in the 
NASh, has been shown to alleviate depression and addiction related symptoms (Crofton et al., 
2017). 
 
Another important signalling pathway linked to the cognitive symptoms of neuropsychiatric 
disorders is the mammalian target of rapamycin (mTOR). mTOR signaling regulates cell 
metabolism, proliferation, and growth. mTOR nucleates two distinct protein complexes: mTOR 
complex 1 (mTORC1), which acts as a cell energy sensor and controls protein synthesis based on 
the availability of nutrients (Kim et al., 2002); and the mTOR complex 2 (mTORC2), which 
phosphorylates protein kinase B (Akt) and is involved in the regulation of the cytoskeleton and 
cellular metabolism. Dysregulation of mTOR signalling has been implicated in addiction and 
many neuropsychiatric disorders, including schizophrenia and depression (Bockaert & Marin, 
2015; Meffre et al., 2012; Ryskalin, Limanaqi, Frati, Busceti, & Fornai, 2018). Additionally, the 
rapid antidepressant effect of ketamine has been demonstrated to be mediated by mTOR (Li et 
al., 2010). Interestingly, both THC and CBD alter the Wnt and mTOR pathways, which may 
potentially explain their neuropsychotropic properties. For example, previous studies have 
demonstrated that chronic exposure to THC during adolescent neurodevelopment inhibits GSK3 
and mTOR signalling pathways directly in the mPFC (Renard et al., 2017). Furthermore,  CBD 
can block amphetamine-induced behavioural sensitization through activation of  mTOR or 
p706K pathways directly in the nucleus accumbens shell (Renard et al., 2016). Taken together, 
this evidence implicates the Wnt and mTOR pathways as being important players in affective 
and cognitive processing within the mesocorticolimbic circuitry.  
 
1.5  SUMMARY AND RATIONALE 
As discussed above, the specific phytochemical compounds in cannabis can exert a wide range 
of effects throughout the brain and strongly alter behaviour, cellular activity, and intra-cellular 
signalling pathways. The mesolimbic reward pathway is of importance given its role in 
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cognition, motivation, reward, emotion and memory processing. Although considerable research 
attention has been dedicated to studying the phytochemical compounds in cannabis, we still 
understand relatively little about how THC and CBD exert their effects on cognitive and 
affective processing within the mesocorticolimbic circuitry. Given the well-established potential 
for both detrimental and therapeutic effects of cannabis-derived phytochemicals, the studies 
reported in this thesis aim to more clearly elucidate how and where THC and CBD may produce 
neuropsychiatric effects within the mesocorticolimbic system. 
 
1.5.1  General hypothesis 
My overarching hypothesis is that CBD and THC will differentially affect cognition, emotional 
associative memory and affective processing via dissociable molecular, neuronal, 
pharmacological, and anatomical mechanisms directly in the mammalian NAc. My thesis will 
address this general hypothesis with the following three specific research aims: 
 
AIM 1. Investigate and characterize the effects of intra-NASh CBD on the formation 
of associative fear memory through functional interactions with the serotonergic 5-
HT1A signalling pathway and associated modulation of VTA neuronal network 
dynamics. (Chapter 2) 
 
AIM 2. Investigate and characterize the behavioural and neuronal effects of intra-
NASh THC on reward and aversion processing within anatomically dissociable 
regions of the NASh and identify the potential role of separate opioid receptor 
substrates underlying these dissociable effects. (Chapter 3) 
 
AIM 3. Investigate and differentiate the localized molecular signalling mechanisms 
underlying the effects of THC in the anterior vs. posterior poles of the NASh as it 
relates to fear-related associative memory, anxiety and sensorimotor 
gating phenomena. (Chapter 4) 
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CHAPTER 2 
 
 
2 Cannabidiol Modulates Fear Memory Formation Through 
Interactions with Serotonergic Transmission in the Mesolimbic 
System1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 This chapter has been adapted from the published journal article: Norris C, Loureiro M, Kramar C, Zunder J, 
Renard R, Rushlow W, and Laviolette, SR. (2016). Cannabidiol Modulates Fear Memory Formation Through 
Interactions with Serotonergic Transmission in the Mesolimbic System. Neuropsychopharmacology; 41: 2839-2850  
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2.1 INTRODUCTION 
There is ongoing debate regarding the potential therapeutic potential of cannabis-derived 
phytochemicals in the treatment of neuropsychiatric conditions. Central to this debate is 
emerging evidence demonstrating that separate phytochemical constituents of cannabis may 
possess differential pharmacological and psychotropic effects. Although delta-9- 
tetrahydrocannabinol (THC) is considered the primary psychoactive component of marijuana, 
cannabis contains over 100 distinct compounds (ElSohly & Slade, 2005; Radwan et al., 2009). 
Of these, cannabidiol (CBD), which is considered non-psychoactive, is the most abundant. In 
contrast to THC, CBD can act as an antagonist or inverse agonist of the CB1 receptor (CB1R; 
(Pertwee, 2008; Thomas, Gilliam, Burch, Roche, & Seltzman, 1998), is an agonist at the 5-HT1A 
receptor (Russo et al., 2005) and decreases cellular reuptake and hydrolysis of the 
endocannabinoid anandamide, potentiating its central effects (Bisogno et al., 2001).  
In terms of psychotropic profiles, THC is associated with transient and long-term 
psychotomimetic effects (Bhattacharyya et al., 2012; Murray, Morrison, Henquet, & Di Forti, 
2007) whereas clinical and pre-clinical research has shown that CBD can produce antipsychotic 
and anxiolytic effects (Campos, Ferreira, & Guimarães, 2012; Casarotto, Gomes, Resstel, & 
Guimarães, 2010; Crippa et al., 2011; Fogaca, Reis, Campos, & Guimarães, 2014; Gomes et al., 
2015; Leweke et al., 2012; Mechoulam, Peters, Murillo-Rodriguez, & Hanuš, 2007; Renard et 
al., 2016; Schubart et al., 2014; Zuardi et al., 2006, 2012). In addition, CBD may modulate 
emotional memory processing and decrease symptoms associated with emotional memory 
disorders such as post-traumatic stress disorder (PTSD; Betthauser, Pilz, & Vollmer, 2015; 
Blessing et al., 2015).  
 
While the precise neuroanatomical regions responsible for CBD’s actions are not known, 
considerable evidence implicates the nucleus accumbens (NAc) as an important site for CBD’s 
modulatory effects on various cognitive and behavioural phenomena (Bhattacharyya et al., 2009; 
Guimarães, Zuardi, Del Bel, & Guimarães, 2004; Mijangos-Moreno, Poot-Aké, Arankowsky-
Sandoval, & Murillo-Rodríguez, 2014; Pedrazzi, Issy, Gomes, Guimarães, & Del-Bel, 2015; 
Valvassori et al., 2011). For example, CBD attenuates THC-induced dysregulation of the ventral 
striatum during verbal recall tasks (Bhattacharyya et al., 2009) and increases c-fos and adenosine 
  27 
levels in rodent NAc (Guimarães et al., 2004; Mijangos-Moreno et al., 2014). In addition, CBD 
blocks amphetamine-induced oxidative stress in the NAc (Valvassori et al., 2011) and intra-NAc 
CBD attenuates the disruptive effects of amphetamine on pre-pulse inhibition (PPI) (Pedrazzi et 
al., 2015). Nevertheless, the precise functional and pharmacological mechanisms by which CBD 
may produce these effects in the mesolimbic system are not currently understood.  
 
In the present study, we investigated the potential effects of CBD on fear-related memory 
formation and how CBD may modulate neuronal activity states within the mesolimbic circuitry. 
Using a combination of behavioural conditioning and in vivo neuronal electrophysiological 
recordings, we report that intra-NAc CBD dose-dependently blocks the formation of associative 
fear memories and blunts the activity levels of DAergic neuronal activity in the ventral tegmental 
area (VTA). Furthermore, these effects were dependent upon intra-NASh 5-HT1A receptor 
transmission and functional interactions between the NASh and GABAergic transmission in the 
VTA.  
 
2.2 MATERIALS AND METHODS 
2.2.1 Animals and Surgery 
 Male Sprague–Dawley rats (300–350 g; Charles River, Senneville, QC, Canada) were 
anesthetized with ketamine (80 mg/ml)–xylazine (6 mg/kg; intraperitoneally) and placed in a 
stereotaxic apparatus. An incision was made to expose the skull, and stainless steel guide 
cannulae (22 G; Plastics1) were implanted into the NASh using the following stereo- taxic 
coordinates (12° angle, mm from bregma): antero- posterior (AP) +1.8, lateral (LAT) ± 2.6, and 
ventral (V) − 7.4 from the dural surface and the following coordinates for the VTA (10° angle, 
mm from bregma): AP − 5.0, LAT ± 2.6, and V − 8.0 from the dural surface. Coordinates were 
based on the Atlas of Paxinos and Watson (2005). Rats in the NASh-VTA disconnection groups 
received single uni- lateral NASh cannulation and contralateral VTA cannulation. All 
experimental procedures were performed in accordance with the regulations of the Canadian 
Council on animal care (CCAC) and the University of Western Ontario. 
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2.2.2 Drug Administration 
The broad-spectrum DA receptor antagonist, α-flupenthixol (α-flu; Tocris), the GABAA 
antagonist, bicuculline methiodide (Tocris), and the GABAA antagonist, hydroxysaclofen 
(Tocris), were dissolved in physiological saline (pH adjusted to 7.4). The 5-HT1A receptor 
antagonist, NAD 299 hydro- chloride (Tocris), CBD (Tocris), and CB1R antagonist, SR141716A 
(rimonabant, RIM), were first dissolved in dimethyl sulfoxide (DMSO) and then diluted in PBS 
for a final 1% DMSO in PBS vehicle (VEH) solution. Microinfusions were performed over 1 
min through a Hamilton microsyringe. To ensure adequate diffusion, injector cannulae were left 
in place for an additional 1 min.  
2.2.3 Olfactory Fear Conditioning 
We used a previously described olfactory fear conditioning paradigm to measure fear memory 
formation (Draycott et al., 2014; Lauzon, Bishop, & Laviolette, 2009). Two distinct 
environments were used. Environment A was a 30 in× 30 in Plexiglass box with black spots on a 
white background and environment B was a 30 in× 30 in Plexiglass box with black and white 
stripes. The designated shock environment had a metallic grid shock floor, while the designated 
test environment had a smooth gray Plexiglas floor. The environments were assigned as ‘shock’ 
and ‘test’ in a counterbalanced manner such that all rats with ‘shock’ environment A were tested 
in environment B and all rats with ‘shock’ environment B were tested in environment A. On day 
1 (habituation), rats were given sham microinfusions into the NASh and habituated to both 
conditioning environments for 30 min. Footshocks were delivered at an intensity of 0.8 mA (for 
1 s), which we have previously reported to produce highly robust conditioned freezing 
behaviours (Draycott et al., 2014; Lauzon et al., 2009). On day 2 (conditioning phase), rats were 
returned to the room and, immediately before being placed in previously assigned ‘shock’ 
environment, rats received intra-NASh microinfusions of CBD (1, 10, and 100 ng/ 0.5 μl); the 
DA antagonist α-flu (100 ng–1.0 μg/0.5 μl), alone or in combination with CBD; the 5-HT1A 
antagonist NAD 299 hydrochloride (10–100 ng/0.5 μl), alone or in combination with CBD (100 
ng). Two odors were delivered during conditioning, almond and peppermint. One odor was 
presented with a footshock (CS+) and the other was presented in the absence of a footshock (CS 
-). After 1 min in the ‘shock’ environment, the CS− odor was presented for 20 s. After 2 min, the 
CS+ odor was presented for 19 s followed by a 1 s footshock delivered through the shock floor. 
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This cycle was repeated five times. On day 3 (test phase), rats were placed in the previously 
assigned test environment. They were given 1 min to explore the environment before odor 
presentations began, during which time baseline levels of freezing behaviour were recorded. 
Both CS+ and CS− odors were presented in a fully counter- balanced order for 5 min and 
amounts of time rat’s spent freezing (lack of movement except for respiration) was recorded and 
analyzed with ANY-MAZE video software for offline analysis. 
 
2.2.4 Footshock Sensitivity Tests 
To ensure that intra-NASh infusions of CBD, NAD 299, or α-flu were having no effect on 
baseline sensitivity to footshock stimulation during fear memory acquisition, separate control 
groups received either bilateral intra-NASh microinfusions of VEH, CBD (100 ng/0.5 μl), NAD 
299 (500 ng/0.5 μl), or α-flu (1000 ng/0.5 μl) alone immediately before a sensitivity testing 
phase wherein rats received five test shock administrations (0.8 mA, 1 s, in the absence of any 
cue delivery), once per minute over a total of 5 min. During this time, levels of freezing 
behaviour, total distance traveled, and the number of jumping events were recorded with ANY- 
MAZE video software and analyzed offline. 
 
2.2.5 In Vivo Electrophysiological Recordings 
In vivo single-cell extracellular VTA recordings were performed as described previously 
(Loureiro, Renard, Zunder, & Laviolette, 2015; Tan, Bishop, Lauzon, Sun, & Laviolette, 2009). 
Briefly, rats were anesthetized with urethane (1.4 g/kg, intraperitoneally) and placed in a 
stereotaxic frame with body temperature maintained at 37 °C. A scalp incision was made, and 
holes were drilled in the skull above the NASh and VTA. For intra-NASh microinfusion of CBD 
(100 ng/0.5 μl), a 1 μl Hamilton syringe was slowly lowered at the same coordinates used for 
behavioural studies. For intra- VTA extracellular recording, glass microelectrodes (with an 
average impedance of 6–8MΩ) filled with a 2% Pontamine Sky Blue solution were lowered 
using a hydraulic micro- positioner (Kopf 640) at the following flat skull stereotaxic coordinates 
(in mm from bregma): AP − 5.3, LAT ± 0.7 from midline, ventral (V) − 7.0 to − 8.5 from the 
dural surface. Extracellular signals were amplified using a MultiClamp 700B amplifier 
(Molecular Devices) and recorded through a Digidata 1440A acquisition system (Molecular 
Devices) using the pClamp 10 software. Extracellular recordings were filtered at 1 kHz and 
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sampled at 25 kHz. VTA DA neurons were identified according to well-established 
electrophysio- logical features (Jalabert et al., 2011; Ungless, Ungless, Magill, & Bolam, 2004): 
(1) a relatively long action potential width (>2.5 ms); (2) a slow spontaneous firing rate (2–5 
Hz); (3) a biphasic waveform consisting of a notch on the rising phase followed by a delayed 
after potential; and (4) a single irregular or bursting firing pattern. VTA GABA interneurons 
were also characterized based on previously reported criteria: (1) a narrow action potential width 
(<1 ms); (2) relatively fast firing rates (typically between 10 and 20 Hz); and (3) the absence of 
bursting activity. Neurons that failed to clearly meet the aforementioned criteria for VTA DA or 
VTA non-DA electrophysiological neuronal properties were excluded from post experimental 
analyses. Recordings analyses were accomplished using the Clampfit 10 software. Response 
patterns of isolated VTA neurons following intra-NASh CBD micro-infusions were determined 
by comparing neuronal frequency rates between the 5 min preinfusion vs postinfusion epochs. 
Classification of drug-infusion effects used a criterion of a ≥10% increase in firing frequency 
postinfusion to be classified as an increase; a ≤10% decrease to be classified as a decrease. 
Neurons showing firing frequency parameters within these cut-off points were classified as ‘no 
change’. For VTA DA neurons, we also analyzed the bursting rate and number of spikes within 
each burst. The onset of a burst was defined as the occurrence of two consecutive spikes with an 
interspike interval of <80 ms. For histological analysis of extracellular VTA neuronal recording 
sites, recording electrode positions were marked with iontophoretic deposit of Pontamine Sky 
Blue dye (−20 μA, continuous current for 12–15 min). Rats were then perfused transcardially 
with isotonic saline followed by 10% formalin. Brains were removed and stored in a 25% 
sucrose-formalin solution before sectioning (40 μm sections) on a freezing cryostat. Following 
this, sections were stained with neutral red and infusion and/or neuronal recording sites were 
confirmed with light microscopy. 
 
2.2.6 NASh–VTA Functional Disconnection Studies 
Previous research has established the functional connectivity between the NAc and the VTA, 
whereby GABAergic projections from the NAc are capable of modulating VTA DAergic and 
non-DAergic neuronal activity states (Kalivas, Churchill, & Klitenick, 1993; Nauta, Smith, 
Faull, & Domesick, 1978). To determine if the behavioural effects of intra-NASh CBD were due 
to modulatory influences from the NASh→VTA, we performed a functional disconnection 
  31 
procedure, similar to one described previously (Rosen et al., 2015). In this procedure, to 
disconnect the effects of intra-NASh CBD from intra-VTA GABAergic transmission, 
experimental groups had micro- injector cannulae placed unilaterally in the NASh of one 
hemisphere, and the VTA of the contralateral hemisphere. Group 1 received intra-VTA VEH 
followed by intra-NASh VEH. Group 2 received intra-VTA VEH followed by intra- NASh CBD 
(100 ng/0.5 μl). Group 3 received intra-VTA microinfusion of the GABAA receptor antagonist 
bicuculline methiodide (50 ng/0.5 μl) with the selective GABAB antagonist hydroxysaclofen 
(100 ng/0.5 μl), followed by intra-NASh CBD (100 ng/0.5 μl). Group 4 received the intra-VTA 
bicuculline/hydroxysaclofen mixture followed by intra- NASh VEH. All groups received the 
intra-VTA treatment 2 min before intra-NASh treatments. The hemispheres for 
unilateral/contralateral cannulations were counter-balanced within groups to control for 
laterality. All groups were then subjected to the same olfactory fear conditioning paradigm 
described above. 
 
2.2.7 Data Analysis 
Data were analyzed with one- or two-way ANOVA, followed by post hoc paired-samples t-tests 
or Newman–Keuls tests, where appropriate. 
 
2.3 RESULTS  
2.3.1 Histological Analyses 
Histological analysis revealed injector placements localized within the anatomical boundaries of 
the shell subdivision of the NAc or VTA, according to (Paxinos and Watson (2005). Figure 2.1 
presents a microphotograph displaying a typical injector placement within the NASh, relative to 
the ‘core’ subdivision. Figure 2.1 displays a schematic illustration showing representative intra-
NASh cannulae placements along the rostral–caudal axis of the NAc. Black circles represent 
VEH control rats receiving for shows a micro- photograph displaying typical bilateral intra-
NASh injector placements. 
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Figure 2.1 Histological analysis of intra-NASh microinjection sites. A, Microphotograph of a 
representative injector placement within the shell subdivision of the NAc. B, Schematic 
representation of select intra-NASh injector locations; • = 100ng CBD group,  = 100ng CBD + 
500ng NAD299 group. C, Microphotograph of representative intra-NASh bilateral cannulae 
placements. 
 
2.3.2  Intra-NASh CBD Dose-Dependently Blocks the Formation of 
Associative Fear Memory 
We first examined the potential effects of intra-NASh CBD on the acquisition of associative fear 
memory (see Materials and Methods). Using a wide dose range of bilateral intra-NASh CBD (1 
ng–100 ng/0.5 μl), we challenged the acquisition of fear memory by administering CBD 
immediately before the fear conditioning session. ANOVA comparing percentages of time spent 
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freezing during testing revealed a significant main effect of group (F(7,287) = 5.75, p = 0.0001). 
Post hoc analyses revealed that whereas rats treated with intra-NASh VEH (n = 6) and rats 
treated with a lower dose of CBD (1 ng/0.5 μl, n = 7) spent significantly greater amounts of time 
freezing in the presence of the CS+ (p’s <0.05, 0.01, respectively), rats receiving either 10 ng (n 
= 8) or 100 ng (n = 6) of intra-NASh CBD showed no associative freezing in response to CS− vs 
CS+ cue presentations (p’s > 0.05; Figure 2.2a). In addition, associative freezing in response to 
CS+ presentations were significantly lower relative to VEH controls for both the 10 ng and 100 
ng CBD groups (p’s < 0.01; Figure 2.2a). Thus, bilateral intra- NASh CBD dose-dependently 
blocks the formation of conditioned fear memories measured with conditioned freezing 
behaviours. Accordingly, we selected the highest behaviourally effective dose of 100 ng/0.5 μl as 
the challenge dose for subsequent behavioural and electrophysiological experiments. 
 
2.3.3  Intra-NASh CBD Modulates Fear Memory Formation Through a 5-
HT1A-Dependent Mechanism 
Given previous evidence demonstrating that CBD produces its pharmacological effects via the 5-
HT1A receptor (Russo et al, 2005), we next challenged the effects of intra-NASh CBD (100 ng) 
with co-administration of the selective 5-HT1A receptor antagonist, NAD 299 (10–100 ng/0.5 μl). 
ANOVA comparing percentages of time spent freezing during testing revealed a significant main 
effect of treatment (F(1,37) = 13.9; p < 0.001). Post hoc analyses revealed that rats receiving either 
the lower (10 ng/0.5 μl) or higher (100 ng/0.5 μl) dose of NAD 299 (10 ng, n = 7; 100 ng, n = 6) 
with CBD, demonstrated robust associative freezing behaviours in response to CS+ 
presentations, relative to VEH controls (n = 7, p’s < 0.01; Figure 2.2b). To control for the 
potential effects of NAD 299 alone, a separate control group received bilateral intra-NASh NAD 
299 (100 ng/0.5 μl; n = 8) alone, before training. These rats displayed normal conditioned 
freezing behaviour, freezing significantly more to CS+ presentations (p < 0.05). Next, to 
examine the possible involvement of DA receptor transmission in the effects of intra-NASh 
CBD, we challenged the effects of intra-NASh CBD with the broad-spectrum DA receptor 
antagonist, α-flu (100–1000 ng/0.5 μl). ANOVA revealed a significant main effect of group 
(F(3,50) = 5.65; p < 0.01) on times spent freezing to CS+ vs CS− presentations. Post hoc analyses 
revealed that rats receiving co-administration of CBD (100 ng/0.5 μl) with either the lower dose 
of α-flu (100 ng/ 0.5 μl; n = 6) or the higher dose of α-flu (1000 ng/0.5 μl; n = 8) showed no 
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associative freezing during CS+ presentations (p’s > 0.05; Figure 2.2b). To control for any 
potential effects of α-flu alone on fear memory formation, a separate control group (n = 8) 
received intra-NASh α-flu alone (1000 ng/0.5 μl). This group demonstrated significant 
associative freezing behaviours (p < 0.05; Figure 2.2b). Thus, whereas 5-HT1A receptor 
blockade reversed the effects of CBD-induced block of fear memory acquisition, DA receptor 
blockade had no effect. In addition, neither the highest behaviourally effective doses of NAD 
299 nor α-flu produced any effects on fear memory acquisition in and of themselves. 
 
Beyond the 5-HT1A receptor system, previous studies have suggested that CBD may produce 
pharmacological actions on the CB1 receptor system (McPartland, Duncan, Di Marzo, & 
Pertwee, 2015). To examine if the effects of CBD on fear memory acquisition may be mediated 
through a CB1 receptor substrate, separate groups of rats received intra-NASh CBD (100 ng/0.5 
μl) co-administered with the selective CB1 antagonist, RIM (50–500 ng/0.5 μl; n = 9, n = 10, 
respectively). Comparing the effects of RIM/CBD co-administration on freezing behaviours 
revealed a significant effect of group (F(2,47) = 10.53; p < 0.01), with post hoc analyses revealing 
that neither dose of RIM reversed the effects of CBD on fear memory blockade, relative to VEH 
controls, with both groups displaying no associative freezing in response to CS+ vs CS− 
presentations (p’s > 0.05; Figure 2.2b). To ensure that the highest doses of CBD, NAD 299, or 
α-flu were not producing any unconditioned effects on footshock sensitivity during the fear 
memory acquisition phase, separate control groups received footshock sensitivity tests (see 
Materials and Methods) following bilateral intra-NASh microinfusions of VEH (n = 8), CBD 
(100 ng/0.5 μl, n = 7), NAD 299 (500 ng/0.5 μl, n = 8), or α-flu (1000 ng/ 0.5 μl, n = 8). Group 
comparisons with ANOVA revealed no significant group differences in the amount of 
freezing behaviour following footshock (0.8 mA) administration (F(3,29) = 1.10; p > 0.05; Figure 
2.2b); total distance traveled during the sensitivity testing (F(3,29) = 0.92; p > 0.05; Figure 2.2d) 
or total average number of jumping events during footshock administrations (F(3,29) = 0.25; p > 
0.05; Figure 2.2b). Thus, neither CBD, NAD 299 nor α-flu produced any observable alterations 
in footshock sensitivity during fear memory acquisition training.  
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Figure 2.2  Effects of intra-NASh CBD on olfactory fear memory acquisition: modulation 
by 5-HT1A receptor transmission. A, Relative to vehicle control rats, bilateral administration 
of intra-NASh CBD (1-100 ng/ 0.5 µl) dose-dependently blocks the acquisition of supra-
threshold (0.8 mA) olfactory associative fear memory. B, The effects of intra-NASh CBD on 
associative fear memory formation are dose-dependently reversed by co-administration of a 
selective 5-HT1A receptor antagonist (NAD 299, 10- 100 ng/ 0.5µl), but not by the broad-
spectrum DA receptor antagonist, -flu (100-1000 ng/0.5 µl) or the CB1 receptor selective 
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antagonist, rimonabant (50-500 ng/0.5 µl). Neither intra-NASh NAD 299 (500 ng) nor -flu 
(1000 ng) administered alone produce any effects on fear memory formation. * = p <.05; ** = p 
< .01. Bars represent means ± standard error of the mean (S.E.M.) for this and all subsequent 
figures. 
 
2.3.4  Intra-NASh CBD Modulates DAergic vs Non-DAergic Neuronal 
Activity States in the VTA 
We next performed in vivo, single-unit neuronal recordings in the VTA to determine the 
potential effects of intra-NASh CBD administration on spontaneous neuronal activity patterns in 
isolated populations of DAergic vs non-DAergic VTA neurons (see Materials and Methods; 
Figure 2.3a). Accordingly, our previously determined behaviourally effective dose of CBD (100 
ng) was microinfused into the NASh while simultaneously recording single-cell extracellular 
VTA neuronal units. A total of n =15 VTA-DA neurons were recorded and analyzed following 
intra-NASh CBD micro- infusions. A cell was considered to have changed its firing rate if there 
was a minimum of 10% difference in frequency rate from baseline. Using this previously 
established and reported criterion (Draycott et al., 2014; Tan et al., 2009), qualitative analysis 
revealed that 60% of DA neurons showed decreased activity, 7% increased, and 33% were 
unchanged (Figure 2.3b). Subgroup analyses of average frequency recorded during 5 min pre- 
vs post-intra-NASh microinfusions revealed that CBD significantly decreased the firing rate (t(14) 
= 3.13, p < 0.01; Figure 2.3c) and bursting rate (t(14) = 2.76, p < 0.05) without significantly 
decreasing the number of spikes per burst (t(14) = 2.06, p = 0.06) (Figure 2.3d). Thus, intra-NASh 
CBD (100 ng) causes a predominantly inhibitory effect on VTA DAergic neuronal frequency 
and bursting rates. In Figure 2.3e, we present a rastergram of a single VTA DA neuron showing 
a typical decreased activity pattern following intra-NASh CBD microinfusion. We next recorded 
and analyzed presumptive VTA GABA neurons (n = 15) during intra-NASh CBD (100 ng) 
administration. Qualitative analysis of overall population activity revealed that 27% of non-DA 
neurons decreased activity, 40% increased, and 33% demonstrated no significant change in 
frequency (Figure 2.3f). Statistical analyses of neuronal sub- populations recorded 5 min pre- vs 
post-NASh microinfusions showed that while CBD did not significantly modify the collective 
(group) firing frequency of VTA GABA interneurons (t(14) = 0.04; p= 0.97) separate sub-
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population analyses revealed that neurons showing increased activity were significantly elevated 
in firing frequency relative to baseline (t(5) = 3.8; p < 0.01; Figure 2.3g), whereas neurons 
showing either decreased (t(3) = 2.9; p > 0.05) or no change in activity (t(4) = 0.55; p > 0.05) were 
not significantly changed from preinfusion baseline levels (data not shown). Collectively, these 
data demonstrate that intra-NASh CBD induces heterogeneous effects on presumptive VTA 
GABAergic neurons. However, a plurality of these neurons (40%) significantly increased their 
spontaneous firing rates. In Figure 2.3h, we present a rastergram showing a typical non- 
DAergic neuronal response pattern following intra-NASh CBD microinfusion.  
 
 
Figure 2.3 Effects of intra-NASh CBD on DAergic and non-DAergic neuronal activity 
patterns in the ventral tegmental area. A, Representative microphotograph showing typical 
intra-VTA in vivo DA neuron recording location (indicated by black arrow). B, Group summary 
of all VTA DA neuronal effects showing distribution of neuronal response patterns (no change in 
frequency, decreased activity, increased activity) across experimental conditions. C, Intra-NASh 
CBD significantly decreased spontaneous VTA DA neuronal firing frequency and D, bursting 
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rates. E, Sample rastergram showing typical VTA DAergic neuronal response pattern following 
intra-NASh CBD (100 ng/0.5 ml) administration. F, Summary of non-DA neuronal group 
response patterns following intra-NASh CBD administration. G, A sub-population of non-
DAergic VTA neurons show a significant increase in spontaneous firing frequency following 
intra-NASh CBD (100 ng/0.5 ml). H, Sample rastergram showing a typical VTA non-DA 
neuronal response pattern following intra-NASh CBD administration 
2.3.5  CBD Modulates DAergic Neuronal Activity in the VTA Selectively 
Through NASh 5-HT1A Transmission 
We next sought to determine how the effects of co-administration of selective 5-HT1A or DA 
receptor antagonists on CBD-mediated behaviours might influence VTA DAergic neuronal 
activity. Accordingly, we performed in vivo, single-unit intra-VTA neuronal recordings to 
determine the potential effects of intra-NASh CBD, NAD 299/CBD, or α-flu/CBD co-
administration on VTA DA neuron firing frequency and bursting levels (see Materials and 
Methods), using our behaviourally effective doses of CBD (100 ng/0.5 μl), NAD 299 (100 ng/0.5 
μl), or α-flu (1 μg/0.5 μl). We sampled a total of n = 44 VTA DA neurons (VEH group, n =10 
cells; CBD (100 ng) group, n =15 cells; CBD (100 ng) + NAD 299 (100 ng) group, n =10 cells; 
CBD (100 ng) + α-flu (1000 ng), n = 9 cells). A summary of VTA DAergic neuronal activity 
profiles after intra-NASh microinfusions are represented in Figure 2.4a. For rats receiving intra-
NASh VEH, 50% of neurons showed no change, 30% increased, and 20% showed decreased 
activity. For rats receiving intra-NASh CBD, 60% of neurons decreased firing frequency, 33% 
showed no change, and 7% increased frequency. In rats receiving intra- NASh CBD+NAD 299, 
neurons decreasing, increasing, or showing no change in activity levels were 60%, 20%, and 
20%, respectively. In rats microinfused with CBD + α-flu, 78% of the recorded cells decreased 
their firing frequency, 22% showed no change, and no cells demonstrated increased frequency. 
Analyses of pre- vs postinfusion activity rates for VTA DA neurons revealed average changes 
from baseline of +7% for rats treated with VEH, −27% for rats treated with CBD, +3% with 
CBD + NAD 299, and −23% for rats microinfused with CBD + α-flu (Figure 2.4b). ANOVA 
comparing groups revealed a significant main effect of treatment on VTA DA neuron firing 
frequency rates (F(3,43) = 3.57, p < .05). Post hoc analysis revealed that rats treated with intra-
NASh CBD alone or with CBD + α-flu showed significantly decreased firing frequencies relative 
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to baseline (p’s < .05). However, rats treated with CBD + NAD 299 showed significantly 
increased firing frequency relative to these groups, and no significant difference from baseline 
levels (p < 0.05; Figure 2.4b). Thus, cotreatment with NAD 299, but not α-flu, reversed CBD-
induced reductions in spontaneous DA neuron frequency rates. Analysis of VTA DA neuron 
bursting rates revealed average changes from baseline of −4%, −35%, +29%, and −40% for rats 
treated with intra-NASh VEH, CBD, CBD + NAD 299, and CBD + α-flu, respectively (Figure 
2.4c). ANOVA comparing groups revealed a significant effect of treatment (F(3,43) = 4.24, p < 
0.01) and post hoc comparisons showed that bursting rates were significantly different between 
rats treated with CBD vs CBD + NAD 299 (p < .05) and between CBD + α-flu and CBD + NAD 
299 groups (p < .05). Thus, cotreatment with NAD 299, but not α-flu, reversed CBD-induced 
reductions in spontaneous DA neuron bursting rates. Next, to examine if intra-NASh α-flu or 
NAD 299 had any effects on VTA DA neuron frequency or bursting rates in and of themselves, 
separate control groups received either intra-NASh NAD 299 (500 ng/0.5 μl; n = 10 neurons) or 
α-flu (1000 ng/0.5 μl; n = 9 neurons). For intra-NASh NAD 299, qualitative analysis revealed 
that 10% of neurons showed increased, 30% decreased, and 60% no change in frequency (Figure 
2.4d). For intra-NASh α-flu, qualitative analysis revealed that 20% of neurons increased, 35% 
decreased, and 45% showed no changes (Figure 2.4d). ANOVA revealed no significant 
treatment effect on VTA DA neuron firing rates across groups (F(2,28) = 0.63; p > .05; Figure 
2.4e). ANOVA analysis of bursting rates similarly revealed no significant treatment effect on 
DA neuron burst rates across groups (F(2,26) = 1.33; p > 0.05; Figure 2.4f). Thus, neither intra-
NASh NAD 299 nor α-flu had any effects on VTA DA neuron activity parameters in and of 
themselves. Representative neuronal rastergrams showing single VTA DA neuronal response 
patterns following intra-NASh CBD (100 ng alone; Figure 2.4g); CBD (100 ng) + NAD 299 
(100 ng; Figure 2.4h); and CBD (100 ng) + α-flu (1000 ng; Figure 2.4i) demonstrate typically 
observed neuronal activity patterns following these treatments. Taken together, these results 
show that intra-NASh CBD decreases VTA DA neuronal frequency and bursting rates. These 
effects were blocked by confusion of a 5-HT1A antagonist but remained unchanged by the 
confusion of a DA receptor antagonist. 
  
  40 
 
Figure 2.4  Effects of intra-NASh CBD and serotonergic/dopaminergic antagonists on VTA 
DAergic neuronal activity patterns in the ventral tegmental area. A, Summary of 
experimental neuronal groups showing relative changes (no change, increase or decrease) firing 
frequencies following intra-NASh pharmacological treatments. B, Intra- NASh CBD alone (100 
ng/0.5 µl) caused a significant decrease in spontaneous VTA DA neuronal firing frequency rates. 
This inhibitory effect was reversed by co-administration of the effective dose of NAD 299 (500 
ng/0.5 µl). In contrast, co-administration with the DA receptor antagonist, -flu (1 µg/0.5 µl) had 
no effect on CBD’s inhibition of VTA DA neuron activity. C, Comparing VTA DA neuron 
bursting rates revealed that intra-NASh CBD (100 ng/0.5 µl) significantly decreases VTA DA 
neuron bursting rates. Again, this effect was significantly reversed with co-administration of 
NAD 299 (500 ng/0.5 µl). In contrast, co-administration with the DA receptor antagonist, -flu 
(1 µg/0.5 µl) had no effect on CBD’s inhibition of VTA DA neuron bursting rates. D, Intra-
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NASh NAD 299 (500 ng) or -flu (1000 ng) produced heterogeneous effects on spontaneous 
VTA DA neuron activity patterns. However, neither drug alone produced any significant effects 
on firing frequency (E) or bursting rates (F). G, Sample rastergram showing a typical VTA DA 
neuron inhibitory response pattern following intra-NASh CBD. H, Sample rastergram showing a 
typical VTA DA neuron response following co- administration of CBD with NAD 299 and I, 
sample rastergram showing a typical response pattern following co-administration of CBD with 
-flu. 
 
2.3.6  Functional Disconnection of the NASh→VTA Pathway Reverses the 
Effects of Intra-NASh CBD on Fear Memory Formation Medium 
Medium spiny neurons (MSNs) in the NAc send GABAergic terminals to VTA neurons (Kalivas 
et al., 1993; Nauta et al., 1978). Given our previously described finding (Figures 2.3f–h) that 
intra-NASh CBD caused significant increases in non-DA, presumptive VTA GABAergic 
neurons, we hypothesized that the behavioural effects of intra-NASh CBD may depend on 
NAc→VTA GABAergic projections and therefore depend on GABA receptor transmission 
directly in the VTA. Accordingly, using a functional cerebral disconnection procedure (see 
Materials and Methods), we examined whether intra-VTA blockade of GABAergic transmission 
may modulate the ability of intra-NASh CBD to block associative fear memory in rats with 
unilateral cannulae implantations into the NASh and VTA. Rats received a combination of intra-
VTA bicuculline (50 ng) and saclofen (100 ng) to block intra-VTA GABAA/B receptor 
transmission immediately before a unilateral micro- infusion of intra-NASh CBD (100 ng) in the 
contralateral hemisphere (Figure 2.5a). Histological analysis revealed intra-VTA injector 
locations within the anatomical boundaries of the VTA or NASh as defined by Paxinos and 
Watson (2005) (Figures 2.5b and c). ANOVA comparing behavioural associative freezing 
scores across groups revealed a significant main effect of group (F(3,38) =3.261; p ≤ 0.05; Figure 
2.5d) on percentages of time spent freezing to either CS+ or CS− presentations. Post hoc 
analyses revealed that VEH control rats (NASh/ VEH vs VTA/ VEH; n = 6) demonstrated robust 
associative freezing behaviours in response to CS+ presentations (p < 0.01). In contrast, rats 
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receiving the intra-NASh CBD (n = 6; 100 ng/ 0.5 μl) with intra-VTA VEH showed no 
associative fear memory (p > 0.05), consistent with previous results. However, rats receiving 
intra-VTA GABAA/B antagonists before intra- NASh CBD (100 ng/ 0.5 μl) (n = 6) demonstrated 
robust associative freezing behaviours in response to CS+ presentations (p < 0.05), 
demonstrating that contralateral blockade of VTA GABAA/B transmission is sufficient to reverse 
the behavioural effects of intra-NASh CBD on blockade of associative fear memory formation. 
Finally, to ensure that intra-VTA GABAA/B receptor blockade did not in itself influence fear 
memory formation, a separate group received intra-VTA GABAA/B antagonist treatment before 
intra-NASh VEH. Similar to VEH/ VEH-treated controls, these rats displayed significant 
associative fear responses during CS+ presentations (n = 6; p < 0.05). 
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Figure 2.5 Disconnection of NASh/VTA GABAA/B transmission restores associative fear 
memory formation. A, Summary of experimental design for NASh-VTA disconnection 
procedure with sample microphotographs showing representative intra- VTA and intra-NAc 
microinjector placements. B,C, Schematic summaries showing unilateral placements for intra-
VTA microinfusions of the GABAA/B antagonist mixture and intra-NASh CBD microinfusion 
locations (see methods) • = 100ng CBD+ 50ng Saclofen/ 50ng Bicuculine group,  = 100ng 
CBD + saline group. D, Schematic representation of experimental groups with description of 
contralateral intra-VTA vs. intra-NASh treatments. E, Consistent with previous results (Figure. 
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2.2a), intra-NASh CBD effectively blocks formation of associative fear memory in rats receiving 
intra-NASh CBD vs. contralateral intra-VTA VEH, relative to VEH/VEH controls. In contrast, 
rats receiving intra-NASh CBD vs. intra-VTA GABAA/B receptor blockade in the contralateral 
hemisphere, show no blockade of fear memory formation. In addition, rats receiving intra-NASh 
CBD vs. contralateral VTA GABAA/B receptor blockade demonstrate normal fear memory 
formation. 
 
2.4 DISCUSSION 
In the present study, we report that intra-NASh CBD blocks the formation of fear-related 
memory via a 5-HT1A receptor- dependent mechanism. Furthermore, we found that intra-NASh 
CBD decreased spontaneous VTA DAergic neuronal activity, both in terms of frequency and 
bursting levels, and conversely, increased the spontaneous activity of non-DAergic, presumptive 
VTA GABAergic neurons. CBD’s modulation of VTA DAergic neuronal activity was dependent 
on intra-NASh 5-HT1A transmission, but not DAergic or CB1 receptor transmission, as only 
blockade of 5-HT1A transmission reversed the effects of CBD on VTA DAergic activity states 
and restored associative fear memory formation. Finally, consistent with our electrophysiological 
findings, functional disconnection of GABAergic transmission between the contralateral NASh 
and VTA reversed the effects of intra-NASh CBD on associative fear memory formation. Taken 
together, these findings demonstrate several new insights into the potential role for CBD in the 
modulation of emotional memory processing within the mesolimbic pathway, implicating 
serotonergic transmission as an important mediator of these effects. Our findings are consistent 
with previous research demonstrating a role for CBD in modulating emotional memory. For 
example, Stern, Gazarini, Takahashi, Guimarães, and Bertoglio (2012) reported that systemically 
administered CBD could block reconsolidation of associative fear memories in rats in a 
temporally specific manner. Das et al. (2013) reported that systemic CBD could enhance the 
consolidation of fear-related extinction learning in human subjects. Marinho, Vila-Verde, 
Fogaça, and Guimarães, (2015) recently reported that CBD microinfusions into the prelimbic or 
infralimbic regions of rat prefrontal cortex could induce either anxiolytic or anxiogenic effects 
through a 5-HT1A-dependent mechanism. The present findings are the first report that CBD can 
  45 
produce effects on fear-memory acquisition directly in the NAc, via 5-HT1A-dependent 
modulation of VTA neuronal activity. 
 
2.4.1  CBD Modulates Conditioned Freezing Behaviour Through a 5-HT1A-
Dependent Mechanism in the NAc Considerable 
Considerable evidence links the pharmacological and behavioural effects of CBD to the 
serotonergic system. For example, CBD is a 5-HT1A receptor agonist (Russo et al., 2005) and 
systemic CBD modulates the reward-facilitating effects of morphine via 5-HT1A receptors in the 
dorsal raphe nucleus (Katsidoni, Anagnostou, & Panagis, 2013). In addition, CBD has been 
shown to modulate anxiety-like behaviours through actions on the 5-HT1A receptor (Fogaca et 
al., 2014; Marinho et al., 2015). Consistent with the current findings, previous evidence has 
demonstrated that CBD’s ability to interact with the mesolimbic system involves 5-HT1A 
receptor transmission. For example, 5-HT1A activation in the NASh blocks apomorphine-induced 
behaviours in rodents (Fujita et al., 2008), inhibits amphetamine-induced DA release in the rat 
NAc (Ichikawa, Kuroki, Kitchen, & Meltzer, 1995), and reduces striatal DA synthesis (Johnson, 
Tsai, Shahan, & Azzaro, 1993). Given these effects of 5-HT1A activation, blockade of 5-HT1A 
transmission would be expected to counteract the effects of CBD, removing the inhibitory effects 
of intra-NASh CBD on VTA DAergic activity. This prediction is consistent with our electro- 
physiological findings showing that blockade of 5-HT1A transmission restores VTA DAergic 
tone in the presence of CBD and reverses the behavioural effects of CBD on fear memory 
formation. In contrast, co-administration of a DA receptor antagonist or selective CB1 receptor 
antagonist failed to reverse the behavioural effects of CBD. Previous studies have reported that 
CBD can act as an antagonist or inverse agonist of the CB1 receptor (Pertwee, 2008; Thomas et 
al., 1998). However, other reports have found that CBD has relatively low binding affinity and/or 
activity at the CB1 receptor (Bisogno et al., 2001; Thomas et al., 2007). The present findings 
would suggest that, at least within the NASh, CBD produces its effects through non-CB1 
receptor-dependent mechanisms. 
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2.4.2  CBD Modulates Neuronal Activity Patterns in the VTA Through a 5-
HT1A-Dependent Mechanism 
Interestingly, previous studies using systemic CBD administration have reported both effects of 
CBD on spontaneous activity patterns in VTA neuronal populations (French, 1997) or increases 
in mesolimbic DA release (Murillo-Rodríguez, Millán-Aldaco, Palomero-Rivero, Mechoulam, & 
Drucker-Colín, 2006). These discrepancies are likely due to differences in administration routes, 
as the present study exclusively used targeted microinfusions into the NASh vs systemic 
administration. However, it is of interest that systemically applied CBD may be interacting with 
neural circuits extrinsic to the mesocorticolimbic system, which may in turn produce different 
effects on DAergic transmission patterns. Within the VTA, we found that behaviourally effective 
doses of intra-NASh CBD were sufficient to inhibit VTA DAergic activity levels while 
simultaneously increasing the activity states of presumptive inhibitory VTA GABAergic 
neurons. This effect is consistent with previous observations demonstrating that blunting or 
potentiating VTA DAergic neuronal activity can potently modulate the formation of associative 
fear memories. For example, we have reported that activation of CB1 receptors in the rat 
prefrontal cortex can simultaneously block the formation of normally supra-threshold 
conditioned freezing behaviours and inhibit subcortical DAergic activity (Draycott et al., 2014). 
In contrast, overstimulation of DAergic transmission in the PFC can amplify normally non-
salient associative fear conditioning cues (Lauzon et al., 2009).  
 
The present findings suggest that modulation of VTA DAergic activity via CBD/ 5-HT1A-
dependent mechanisms may similarly regulate emotional salience and the acquisition of 
conditioned freezing behaviour via functional interactions with select VTA neuronal populations. 
For example, by blunting VTA DAergic neuronal activity during the acquisition of associative 
fear memory, CBD may serve to block conditioned freezing behaviours. Future studies are 
required to more precisely characterize the effects of CBD across these distinct learning phases 
of emotional memory processing. How might accumbal 5-HT1A transmission modulate upstream 
DAergic mesolimbic transmission? Anatomical evidence demonstrates that NAc GABAergic 
MSNs send functional GABAergic projections to the VTA (Kalivas et al., 1993; Nauta et al., 
1978). In the present study, we found that intra-NASh CBD increased the activity rates of 
presumptive, non-DA GABAergic neurons in the VTA. Accordingly, we hypothesized that intra-
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NASh CBD may regulate VTA DAergic activity (and corresponding fear-related associative 
memory formation) via indirect modulation of GABAergic transmission substrates in the VTA. 
To test this, we performed a disconnection study wherein intra-NASh CBD effects were 
disconnected from the contralateral hemisphere with combined intra-VTA microinfusions of 
GABAA/B receptor antagonists. Consistent with this hypothesis, disconnection blockade of VTA 
GABAergic transmission was capable of reversing the effects of intra-NASh CBD on fear 
memory formation. While beyond the scope of the present study, one interesting implication 
from the present results is that 5-HT1A receptor activation within the NASh might similarly 
modulate downstream VTA neuronal activity states and fear memory formation. Future studies 
are required to investigate these possibilities. 
 
2.4.3 Implications of CBD’s Modulatory Role on Mesolimbic Activity 
The present study adds to a growing body of preclinical and clinical evidence demonstrating that 
CBD can modulate activity states of the mesolimbic DA system, and, in turn, regulate emotional 
processing. Importantly, the ability of CBD to inhibit mesolimbic DAergic activity and blunt 
fear- related memory formation is particularly intriguing given the large body of evidence 
demonstrating that the primary psychoactive phytochemical in cannabis, THC, produces pro-
psychotic effects (Kuepper et al., 2011). Furthermore, in direct contrast to the effects of CBD, 
THC has been shown to induce a state of hyperactive mesolimbic DAergic activity following 
adolescent neurodevelopmental exposure (Renard et al., 2017). In addition, we have recently 
reported that intra-NASh CBD blocks hyper-DAergic activity and psycho- motor sensitization 
induced by amphetamine exposure (Renard et al., 2016). Several clinical and preclinical reports 
have suggested that CBD can reduce anxiety and may serve to ameliorate symptoms associated 
with emotional memory disorders such as PTSD. For example, CBD has been reported to 
facilitate the extinction of previously acquired traumatic or associative fear memories 
(Bitencourt, Pamplona, & Takahashi, 2008; Das et al., 2013; Stern et al., 2012). While currently 
no clinical evidence has reported specific long-term therapeutic effects of CBD in PTSD patient 
populations, PTSD has been associated with dysregulation of 5-HT1A expression levels in brain 
regions responsible for emotional memory and processing, such as the amygdala (Sullivan et al., 
2013). Furthermore, preclinical evidence has shown also that genetic deletion of the 5-HT1A 
receptor in mice leads to potentiated reactivity to fear-related conditioning cues (Klemenhagen, 
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Gordon, David, Hen, & Gross, 2006). Future research is required to more precisely characterize 
the mechanisms by which CBD and 5-HT1A receptor substrates may interact and how these 
processes may, in turn, regulate emotional memory formation. In summary, the present study 
reveals several novel insights regarding the functional effects of CBD on emotional memory 
processing and identifies a 5-HT1A receptor mechanism within the NASh as an underlying 
mechanism by which CBD may regulate mesolimbic activity and modulate the formation of 
associative emotional memories. Furthermore, these findings underscore growing evidence 
demonstrating that differential phytochemical constituents of cannabis (CBD vs THC) can 
produce divergent and opposing effects on DAergic activity states and emotional memory 
behaviours. 
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CHAPTER 3 
 
3 The Bivalent Rewarding and Aversive properties of 9-
tetrahydrocannabinol are Mediated Through Dissociable 
Opioid Receptor Substrates and Neuronal Modulation 
Mechanisms in Distinct Striatal Sub-Regions 
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3.1 INTRODUCTION 
∆9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, strongly 
modulates affective processing via interactions with the mesolimbic circuitry. THC can produce 
both rewarding and aversive effects in humans and other animals (Chen, Paredes, Lowinson, & 
Gardner, 1991; Lepore, Vorel, Lowinson, & Gardner, 1995; Parker & Gillies, 1995) and strongly 
modulates the mesolimbic dopamine (DA) system. For example, acute THC administration in the 
rodent NAc strongly activates ventral tegmental area (VTA) DAergic neuronal activity (Fitoussi, 
Zunder, Han, & Laviolette, 2018) and systemic THC administration directly activates VTA DA 
neurons (French, 1997). In humans, chronic cannabis use has been shown to induce salience 
sensitization to cues associated with cannabis administration, via sensitization of the mesolimbic 
system (Filbey et al., 2016). Nevertheless, the precise neuroanatomical and pharmacological 
mechanisms by which THC regulates affective processing in the mesolimbic pathway are not 
currently understood. 
 
The primary pharmacological target of THC, CB1 receptors (CB1R), are widely distributed 
throughout the brain, including the mesolimbic circuitry. Substantial evidence implicates the 
nucleus accumbens (NAc) as an important area for THC’s effects on cognitive and affective 
processing. For example, systemic THC causes opioid receptor (OR)- dependent DA efflux in 
the NAc (Chen et al., 1990; Chen, Paredes, Lowinson, & Gardner, 1991) and chronic THC 
exposure alters synaptic plasticity within the NAc (Hoffman, Oz, Caulder, & Lupica, 2003). 
Importantly, the NAc is involved in both reward and aversion processing, particularly the medial 
shell sub-region (NASh), which is implicated in motivational salience, the processing of 
emotional stimuli, reinforcement, and addiction (Baliki et al., 2013; Bozarth, 2015; Calipari et 
al., 2016; Saddoris et al., 2015). 
 
The accumbens is a highly complex limbic structure involved in both reward and aversion 
signaling. Previous evidence has identified the anterior pole of the NASh as a region containing 
high concentrations of µ-opioid receptors (Arvidsson et al., 1995). Thus, stimulation of the 
anterior NASh with a µ-opioid receptor (µOR) agonist produces reward while stimulation of the 
posterior NASh with a κ-opioid (κOR) agonist, produces aversion (Castro & Berridge, 2014). In 
addition, there is significant co-localization of CB1Rs and ORs within the NASh region (Pickel, 
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Chan, Kash, Rodríguez, & Mackie, 2004). However, how an exogenous cannabinoid like THC 
might influence striatal affective processing through CB1-OR signaling remains unknown. Given 
that THC serves as a partial CB1 receptor agonist, this evidence may suggest that the differential 
affective stimulus effects of THC might depend upon differential activation of anatomically 
distinct OR subtypes, within the mammalian NAc. 
 
At the neuronal level, medium spiny neuron (MSN) activity states within the NAc are 
functionally linked to reward and aversion processing, with reward states characterized by 
decreased MSN activity levels, and aversive states associated with increased activity (Tasha 
Ahmad, Sun, Lyons, & Laviolette, 2017; Carlezon & Thomas, 2009). Additionally, neuronal 
population activity within the NAc, specifically -oscillations, are associated with the processing 
of reward-related information (Kalenscher, Lansink, Lankelma, & Pennartz, 2010) and 
disturbances in -oscillations are linked to various neuropsychiatric disturbances, including 
schizophrenia-related affective dysregulation (Sun et al., 2011). 
 
In the present study, we investigated the effects of direct microinfusions of THC on reward and 
aversion conditioning, social behaviour and neuronal activity states within the NASh. Using a 
combination of behavioural assays and in vivo neuronal electrophysiology, we report that THC 
infused into the anterior NASh produces µ-opioid receptor dependent reward effects, potentiates 
morphine reward salience, decreases medium spiny neuron activity and increases the power of 
high frequency -oscillations. In contrast, THC in the posterior NASh produces κOR dependent 
aversion effects, impairs social recognition memory, increases medium spiny neuron activity and 
decreases the power of high frequency -oscillations in local field potential recordings. These 
findings reveal critical new insights into the underlying neuronal and pharmacological 
mechanisms responsible for the bivalent motivational effects of THC, directly in the NAc.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Animals and Surgery 
Male Sprague Dawley rats (300 to 350 g; Charles River, Quebec, Canada) were used in 
compliance with the Canadian Council for Animal Care and institutional guidelines. Rats were 
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housed under controlled conditions (12-hour light/dark cycle and food/water access ad libitum). 
Rats were anesthetized with a mixture of ketamine (80 mg/ml) and xylazine (6 mg/ml) and 
placed in a stereotaxic device. The anatomical criteria for defining the anterior vs. posterior poles 
of the NASh were based upon previously reported studies which have anatomically defined these 
sub-regions based upon pharmacologically defined dissociations between positive vs. negative 
affective behavioural outcomes (Castro et al, 2016; Castro and Berridge, 2014; Mahler et al, 
2007; Reynolds and Berridge, 2002; Smith and Berridge, 2007). In addition, pilot CPP studies 
conducted in our laboratory revealed that an anterior-posterior demarcation at > 2.5 mm from 
bregma (anterior) vs. <1.5 mm from bregma (posterior) represented the most reliable boundary 
for producing THC-related CPP vs. THC-related CPA behaviours. Stainless steel guide cannula 
(22 gauge; PlasticsOne) were implanted bilaterally into either the aNASh at the following 
coordinates (Paxinos & Watson, 2005) : anteroposterior (AP): +2.5 mm from bregma, lateral (L): 
±2.6 mm, dorsal-ventral (DV): -7.4 mm from the dural surface, or the pNASh at the following 
coordinates: (AP): +1.5 mm from bregma, (L): ±2.6 mm, (DV): -7.4. Guide cannulae were held 
in place using jeweler’s screws and dental acrylic. After completion of behavioural experiments, 
rats received an overdose of pentobarbital (240 mg/kg, i.p.) and were perfused with isotonic 
saline followed by 10% formalin. Brains were extracted and post-fixed 24 hrs before being 
placed in a 25% formalin-sucrose solution for one week. Brains were sliced (60 μm) using a 
cryostat and stained with Cresyl violet. Injector tips placements were localized using a light 
microscope. Rats with cannula placements found outside the anatomical boundaries of the NASh 
were excluded from data analysis. 
 
3.2.3 Drug Administration 
Rats received intra-NASh microinfusions with either THC (Cayman Chemical, 10-100ng/0.5 µl), 
cyprodime (CYP; Tocris; 500ng or 1µg/ 0.5µl), nor-binaltorphimine dihydrochloride (nor-BNI; 
Tocris; 500ng or 1µg/ 0.5µl), THC co-administered with CYP, or THC co-administered with 
nor-BNI, immediately prior to conditioning. Intra-NASh drugs were delivered via a 28-gauge 
microinfusion syringe over a period of 1 minute. Microinjectors were left in place for an 
additional 1 min to ensure adequate diffusion from the tip. All intracerebral infusions were 0.5 
L total volume per side. Morphine sulfate (Macfarland-Smith) was administered i.p. The intra-
cranial dose selections for the above compounds were based upon our previously published or 
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piloted dose-response curves using these compounds (Ahmad, Lauzon, de Jaeger, & Laviolette, 
2013; Norris et al., 2016) which demonstrated maximal behavioural efficacy and the absence of 
non-specific behavioural side effects. For morphine CPP experiments, rats were injected with 
either morphine (0.05mg/kg) or saline on alternating conditioning days. 
 
3.2.4 Conditioned Place Preference 
All rats were conditioned using an unbiased, fully counterbalanced place conditioning procedure 
as described previously (Ahmad et al., 2013; Laviolette and van der Kooy, 2003). The two 
conditioning environments differed in smell, texture and color. One environment was black, with 
a smooth Plexiglass floor wiped down with 2% acetic acid prior to each conditioning session. 
The other environment was white, with a wire mesh floor covered with woodchips. Prior to 
commencement of CPP conditioning, rats are given a preconditioning phase where they are 
placed into a motivationally neutral gray box for 20 min, 24h prior to start of conditioning. CPP 
conditioning consists of 4 drug-environment and 4 vehicle-environment pairings once per day, 
alternating over an 8-day period. Environmental conditioning exposures are fully 
counterbalanced for both environment assignment and drug/ vehicle presentations. During the 
CPP test phase, rats are placed in a neutral gray zone separating the drug and vehicle 
environments and allowed to move freely for a period of 10 min between environments. Times 
spent in each environment are digitally recorded and analyzed offline. All rats are tested in a 
drug-free state. For experiments examining the effects of intra-NASh THC and/or opioid 
receptor challenges, experimental groups received intra-NASh microinfusions of either THC 
(10-100ng /0.5 µl), cyprodime (500ng-1µg/ 0.5µl), nor-BNI (500ng-1µg/ 0.5µl), THC co-
administered with cyprodime, or THC co-administered with nor-BNI vs. VEH microinfusions. A 
follow-up CPP experiment examine the potential effects of intra-NASh THC on morphine 
reward salience, using a sub-threshold conditioning dose of morphine (0.05 mg/kg, i.p.) which 
we have previously reported does not produce significant morphine CPP in and of itself (Ahmad 
et al, 2013; Ahmad and Laviolette, 2017; Loureiro et al, 2016a). For these experiments, THC or 
VEH control groups received either anterior or posterior THC or VEH microinfusions before 
being injected with either sub-threshold morphine (0.05mg/kg) or saline on alternating 
conditioning days. Thus, the potential motivational effects of intra-NASh THC (rewarding or 
aversive) were balanced across both saline and morphine conditioning sessions.  
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3.2.5 Sucrose Preference Test  
Prior to testing, rats were water deprived for 12 hrs. At testing, rats were given two bottles of a 
2% sucrose solution to drink for 12 hrs. After exposure to the sucrose solution, rats were micro-
infused with either THC (100ng/0.5µl) or vehicle. They were then placed back in their cages and 
given access to one bottle of regular water or one bottle of 2% sucrose solution. After 1 hr, 
bottles were removed and the weight of the bottles pre- vs. post-test were compared to determine 
the amount of each liquid consumed to determine any increased preference for sucrose. 
 
3.2.6 Sociability and Social Memory 
Testing was performed in a rectangular, three-chambered box. For the sociability test, rats were 
placed in the middle chamber for 5 minutes. Following habituation, an unfamiliar male rat was 
placed in one of the side chambers in a rectangular plexiglass cage. The location of the rat was 
counterbalanced between subjects. The subject was then infused with either THC (100ng/ 0.5µl) 
or vehicle in either their aNASh or pNASh. The subject was then allowed to explore the entire 
apparatus for 8 minutes. Entries were defined as all four paws present in one chamber. 
Behavioural performance was expressed using sociability scores (i.e., difference between times 
spent in stranger vs. empty compartments). Next, to evaluate social recognition, each rat was 
tested in an 8-minute session to evaluate social memory. A second, unfamiliar rat was placed in 
the previously empty chamber. The test rat had a choice between the previously encountered rat 
versus the novel, unfamiliar rat. Times spent in each chamber were recorded, and a social 
recognition score (i.e., difference between times spent in the nonfamiliar vs. familiar rat 
chamber) was calculated for each rat. Times spent in each chamber were recorded with a video-
tracking system (ANY- maze) during all tests. A sociability (time spent with the other rat vs. 
time spent with the empty cage) and social recognition score (time spend with the novel rat vs. 
time spent with the novel rat) was calculated for each rat. 
 
3.2.7 In Vivo Electrophysiological Recordings 
In-vivo extracellular recordings were performed as described previously (Lintas et al., 2012; 
Loureiro, Kramar, Renard, Rosen, & Laviolette, 2016b; Loureiro et al., 2015). Rats were 
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anesthetized with urethane (1.4 g/kg, i.p.) and placed in a stereotaxic apparatus with body 
temperature maintained at 37°C. A scalp incision was made to remove the skin above the skull, 
and holes were drilled in the skull above the NASh and the cranial ventricle. For intra-cranial 
ventricle (ICV) microinfusions of THC (1 µg/μL), a 10 μL gastight Hamilton syringe was slowly 
lowered into the cranial ventricle (15˚ angle): AP: -0.9 mm from bregma, LAT ±2.7 mm, DV: -
3.8 mm from the dural surface. For intra-NASh extracellular recording, glass micro-electrodes 
(with an average impedance of 6 to 8 MΩ) filled with a 2% Pontamine Sky Blue solution were 
lowered using a hydraulic micro-positioner (Kopf 640) at the following flat skull stereotaxic 
coordinates: AP: +1.5 or +2.5 mm from bregma, LAT: ± 0.8 mm, DV: -6.0 to -8.0 mm from the 
dural surface. Extracellular signals were amplified using a MultiClamp 700B amplifier 
(Molecular Devices) and recorded through a Digidata 1440A acquisition system (Molecular 
Devices) using pClamp 10 software. Extracellular recordings were filtered at 1 kHz and sampled 
at 25 kHz. NASh medium spiny neurons were identified using previously established criteria. 
Any cells with a spike width of less than 1ms and more than 2ms were excluded from analysis. 
The electrode was used to simultaneously record local field potentials (LFP). Recording analyses 
were performed with Clampfit 10 software. Response patterns of isolated NASh neurons and 
LFPs to microinfusion of THC alone or in combination with either CYP or nor-BNI were 
determined by comparing neuronal frequency rates and local field potentials (LFP) oscillatory 
patterns between the 10-minute pre- vs. post-infusion recording epochs. A cell was considered to 
have changed its firing rate if there was a minimum of 20% difference in frequency rate from 
baseline. The electrode was used to simultaneously record LFPs. LFP signals were uploaded to 
NeuroExplorer decimated at n = 25. LFP signals then had a Butterworth filter applied and a 
Gaussian filter of 4 for smoothing. For histological analysis of extracellular NASh neuronal 
recording sites, recording electrode positions were marked with iontophoretic deposit of 
Pontamine Sky Blue dye (−20 μA, continuous current for 12–15 minutes). Brains were removed 
and post-fixed 24 h before being placed in a 25% formalin-sucrose solution for one week before 
sectioning (60 μm). Following this, sections were stained with neutral red and infusion/ neuronal 
recording sites were confirmed with light microscopy. 
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3.3 RESULTS  
3.3.1 Histological Analysis 
Histological analysis revealed injector placements localized within the anatomical boundaries of 
the shell subdivision of the NASh. Sample NASh microinfusion locations and schematic 
illustration of several experimental groups across the anterior-posterior axis of the NASh are 
shown in Figure 3.1. 
 
Figure 3.1 Histological analysis of intra-NASh microinjection sites. A, Microphotograph of 
representative injector placement within the anterior portion of the nucleus accumbens shell. B, 
Schematic representation of select intra-anterior-NASh injector locations;  = 100 ng THC 
group,  = 100 ng THC + 1 µg CYP. C, Microphotograph of representative intra-anterior-NASh 
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bilateral cannulae placements. D, Microphotograph of representative injector placement within 
the posterior portion of the nucleus accumbens shell. E, Schematic representation of select intra-
anterior-NASh injector locations;  = 100 ng THC group,  = 100 ng THC + 1 µg CYP. F, 
Microphotograph of representative intra-anterior-NASh bilateral cannulae placements 
3.2.2  Intra-NASh THC produces dose-dependent, anatomically dissociable 
reward or aversion effects via separate opioid receptor substrates 
Given previous evidence demonstrating functional differences in anterior vs. posterior NASh 
region in reward vs. aversion processing (Skelly et al., 2010) and evidence demonstrating that 
cannabinoid signaling can modulate reward or aversion signals via MOR vs KOR receptor 
substrates (Ahmad et al., 2013), we first examined the effects of THC (10ng or 100ng/0.5µl), 
directly in the aNASh or pNASh alone, or in combination with selective MOR [CYP(0.5µg and 
1µg/0.5µl)] vs. KOR [Nor-BNI (1µg/0.5µl)] antagonists using a CPP procedure (see methods). 
We hypothesized that aNASh THC would produce rewarding effects through selective MOR 
transmission, whereas pNASh THC would produce aversive behavioural effects through a KOR-
dependent signaling mechanism. First, we examined the potential motivational effects of intra-
aNASh THC. ANOVA comparing time spent in the drug-paired environment and the vehicle 
paired environment between groups revealed a main effect of environment (F(1,110) = 46.094, p < 
.001) and a significant interaction of treatment and environment (F(5,110) = 9.802,  p < .001; 
Figure 3.2A) on times spent in drug vs. VEH-paired environments. Post-hoc analyses showed 
that rats microinfused with the following drugs spent significant more time in the drug-paired 
environment than the vehicle-paired side: THC (100 ng; n = 10; p = .002), THC (100 ng) + CYP 
(0.5 g; n = 10; p = .01), or THC (100 ng) + nor-BNI (1 g; n = 10; p = .002). In contrast, rats 
receiving vehicle (n = 20), a lower dose of THC (10 ng; n = 10), THC (100 ng) + CYP (1 g; n = 
11) displayed no significant difference between time spent in the drug-paired environment and 
the vehicle-paired environment (p < .05; Figure 3.2A). Intra-aNASh CYP (1µg) alone displayed 
no significant difference between time spent in the drug-paired environment and the vehicle-
paired environment (p < .05; Figure 3.2C). These results indicate that bilateral THC in the 
anterior NASh produces dose-dependent conditioned place preference through a OR 
dependent-substrate, independently of KOR transmission.  
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Next, we examined the motivational effects of intra-pNASh THC. Again, using two different 
doses of THC (10ng and 100ng/0.5µl), two doses of the selective KOR antagonist, Nor-BNI 
(0.5µg and 1µg/0.5µl) in combination with the higher dose of THC, Nor-BNI alone (1µg/0.5µl) 
or the higher dose of THC in combination with CYP (1µg/0.5µl). ANOVA comparing difference 
scores between groups reveled a main effect of environment (F(1,116) = 26.584, p < .001) and a 
significant interaction of treatment and environment (F(5,116) = 7.950, p < .001; Figure 3.2B). 
Post-hoc analyses showed that rats microinfused with the following drugs spent significant more 
time in the vehicle-paired environment than the time-paired side: THC (100 ng; n = 11; p = 
.004), THC + nor-BNI (0.5 g; n = 11; p = .009), and THC (100 ng) + CYP (1 g; n = 11; p < 
.001). In contrast, rats receiving vehicle (n = 10) a lower dose of THC (10 ng; n = 10), THC + a 
higher dose of nor-BNI (1 g; n = 11), or nor-BNI alone (1 g; n = 10) displayed no significant 
difference between time spent in the drug-paired environment and the vehicle-paired 
environment (p < .05; Figure 3.2B). Intra-pNASh nor-BNI (1µg) alone displayed no significant 
difference between time spent in the drug-paired environment and the vehicle-paired 
environment (p < .05; Figure 3.2C). Thus, bilateral THC in the posterior NASh produces dose-
dependent conditioned place aversion (CPA). These aversive effects were dose-dependently 
blocked by a selective KOR antagonist, but not by a MOR antagonist. 
 
3.3.3  Intra-aNASh THC potentiates sub-threshold morphine reward 
salience 
Given our findings that aNASh THC produced robust rewarding effects through a MOR-
dependent substrate and previous evidence showing that stimulation of µORs within the NASh 
can potentiate drug reward salience (Richard & Fields, 2016), we next examined how intra-
NASh THC may modulate the motivational effects of an exogenous opioid, morphine, using a 
sub-reward threshold conditioning dose of morphine (0.05 mg/kg; i.p.; see methods). ANOVA 
comparing time spent in the drug-paired environment and vehicle-paired environment between 
rats receiving intra-aNASh vehicle or THC (100 ng) revealed a main effect of environment (F(1, 
26) = 21.224, p < .001) and a significant interaction of treatment and environment (F(1, 26) = 6.172, 
p = .02). Post-hoc analysis revealed that rats receiving intra-aNASh vehicle (n = 8) displayed no 
significant difference between time spent in the drug-paired environment and the vehicle-paired 
environment but rats receiving intra-aNASh THC spent significantly more time in the drug-
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paired environment than the vehicle-paired environment (n = 7; p = .02; Figure 3.2D). ANOVA 
comparing time spent in the drug-paired environment and vehicle-paired environment between 
rats receiving intra-pNASh vehicle (n = 7) or THC (100 ng; n = 6) demonstrated no main effects 
or interaction (p >.05; Figure 3.2D). Thus, consistent with the ability of aNASh THC to produce 
rewarding effects through a MOR-dependent substrate, aNASh THC potentiated the reward 
salience of normally sub-reward threshold CPP. In contrast, THC in the pNASh had no effect on 
sub-threshold morphine CPP behaviours. 
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Figure 3.2 Effects of intra-NASh THC on conditioned place preference: interactions with 
the opioid system. A, Anterior NASh (+2.5mm from bregma) microinfusions of THC dose 
dependently increases preference for the drug paired side. Co-administration of cyprodime, but 
not Nor-BNI dose-dependently restores responding to baseline. B, Posterior NASH (+1.5mm 
from bregma) THC dose dependently decreases preference for the drug paired side. Co-
administration of Nor-BNI, but not cyprodime, dose-dependently restores responding to baseline. 
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C, Infusions of THC (100 ng) into the anterior NASh, but not the posterior NASh, potentiate the 
reward to sub-threshold morphine (0.05 mg/kg) * = p < .05 
3.3.4 Intra-NASh THC has no effect on sucrose reward processing 
To determine if the effects of intra-NASh THC on affective processing may modulate non-drug-
related motivational effects, we next examined the processing of natural, sucrose-related reward 
(see methods). Percent sucrose consumed was determined by dividing the amount of sucrose 
consumed by the amount of total liquid (water plus sucrose) consumed. Analyses showed no 
significant difference between rats receiving intra-aNASh vehicle (n = 7) and intra-aNASh THC 
(n = 8; t(13) = -.051, p > .05) or intra-pNASh vehicle (n = 8) and intra-pNASh THC (n = 8, t(14) = 
.152,  p > .05; Figure 3.3), indicating that the effect of THC on reward and aversion in the NASh 
is drug-specific and does not generalize to natural reward. 
 
 
Figure 3.3 Effects of intra-NASh THC on a sucrose preference test. THC has no significant 
effect on the percent consumption of sucrose vs total liquid consumed.   
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3.3.5 THC modulates social interaction and cognition selectively in the 
posterior NASh 
Previous studies have demonstrated that cannabinoid signaling can strongly modulate 
social behavioural phenomena through actions in the NASh (Skelly et al., 2010). Therefore, we 
examined the potential effects of intra-NASh THC on social motivation behaviours and 
cognition (social memory). A simplified diagram of the experimental procedure is presented in 
Figure 3.4A-B. In phase 1, sociability scores (measuring motivation to interact with a novel rat) 
were calculated by measuring times spent interacting with a novel rat and subtracting times spent 
interacting with an empty box. ANOVA showed a main effect of treatment on Phase 1 sociability 
scores (F(3, 26) = 3.156, p = .042). Post-hoc analyses revealed a significant difference between 
intra-pNASh THC (n = 8) and intra-pNASh vehicle (n = 8; p = .009), intra-aNASh vehicle (n = 
7; p = .029) and intra-aNASh THC (n = 7; p = .038; Figure 3.4C). No significant differences 
were observed between any other groups. In phase 2, social memory scores were calculated by 
taking times spent with a new, novel rat and subtracting times spent with the previously 
encountered, familiar rat. ANOVA showed a main effect of treatment for social memory scores 
(F(3, 26) = 3.516, p = .029). Post-hoc testing revealed a significant difference between intra-
pNASh THC (n = 8) and intra-pNASh vehicle (n = 8; p = .013), intra-aNASh vehicle (n = 7; p = 
.009) and intra-aNASh THC (n = 7; p = .013) (Figure 3.4D). Thus, intra-NASh THC selectively 
impairs natural social motivation and social memory cognition selectively in the posterior region 
of the NASh. 
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Figure 3.4 Effects of intra-NASh THC on social motivation and social recognition. A, B 
Apparatus and rats’ placements for the sociability and social recognition test respectively. C, 
Microinfusions of THC in the pNASh, but not the aNASh, significantly reduced sociability * = p 
<.05. D, Microinfusions of THC in the pNASh, but not the aNASh, significantly reduced social 
recognition * = p < .05. 
 
3.3.6 THC differentially modulates medium spiny neuron activity in anterior 
vs. posterior NASh 
The activity states of NASh MSN neurons are strongly correlated with reward vs. aversive 
motivational states (Carlezon & Thomas, 2009) and we have previously demonstrated that 
cannabinoid CB1 transmission can produce rewarding effects by inhibiting NASh MSN neurons 
or aversive effects by activating these neurons (Ahmad et al., 2017). To determine if the 
anatomically localized effects of THC on reward or aversion were correlated with MSN activity 
state modulation, we next performed in vivo single-unit recordings in the posterior and anterior 
NASh, combined with ICV infusions of THC. We used a dose 10x our highest behaviourally 
effective dose (1µg/µl) for these systemic studies to control for CSF diffusion (see methods). A 
total of n=15 MSNs were sampled in the aNASh (see Figure 3.5A for representative aNASh 
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recording location) and n=14 MSNs in pNASh (see Figure 3.6A for representative pNASh 
recording location). Population analysis of aNASh MSNs revealed that 66.6% showed decreased 
activity, 0% increased, and 33.3% were unchanged, relative to baseline, following THC 
administration (Figure 3.5B). An analysis of average firing frequency recorded 10 min pre vs. 
post ICV THC infusion revealed that THC significantly decreased firing rates in the aNASh (t(14) 
= 2.738, p = .016; Figure 3.5C). A representative rastergram showing a typical inhibitory 
response to THC in the aNASh is shown in Figure 3.5D. 
 
For MSN neurons recorded in the pNASh, population analysis revealed that 14.3% of MSNs 
showed decreased activity, 50% increased and 35.7% showed no change, relative to baseline 
(Figure 3.6B). Analysis of average firing frequencies recorded 10 min pre vs. post ICV THC 
revealed that THC significantly increased firing rates relative to baseline (t(13) = -2.288, p = .04; 
Figure 3.6C). A representative rastergram showing a typical excitatory response pattern to THC 
administration in the pNASh is shown in Figure 3.6D. Thus, whereas THC strongly inhibits 
MSN activity in the aNASh, THC has a predominantly excitatory effect in the pNASh. 
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Figure 3.5 Effects of ICV THC and CYP on anterior NASh medium spiny neurons activity 
patterns. A, Representative microphotograph showing typical intra-aNASh in vivo MSN 
recording location B, Summary of experimental neuronal groups showing relative changes (no 
change, increase, or decrease) in firing frequencies following ICV pharmacological treatments C, 
ICV THC significantly decreased spontaneous aNASh MSN neuronal firing frequency. D, ICV 
THC alone (1µg/μl) caused a significant decrease in spontaneous aNASh MSN neuronal firing 
frequency rates vs baseline activity. This inhibitory effect was reversed by co-administration of 
the effective dose of CYP (10µg/μl). E, Sample rastergram showing typical aNASh MSN 
response pattern following ICV THC (1µg/µl) infusion. F, Sample rastergram showing typical 
aNASh MSN response pattern following ICV THC (1µg/µl) and CYP (10µg/µl) infusion. 
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Figure 3.6 Effects of ICV THC and nor-BNI on MSN activity patterns in the pNASh. A, 
Representative microphotograph showing typical intra-pNASh in vivo MSN recording location. 
B, Summary of experimental neuronal groups showing relative changes (no change, increase, or 
decrease) in firing frequencies following ICV pharmacological treatments. C, ICV THC 
significantly increased spontaneous pNASh MSN neuronal firing frequency. D, ICV THC alone 
(1µg/μl) caused a significant increase in spontaneous aNASh MSN neuronal firing frequency 
rates vs baseline activity. This excitatory effect was reversed by co-administration of the 
effective dose of nor-BNI (10µg/μl). E, Sample rastergram showing typical pNASh MSN 
response pattern following ICV THC (1µg/µl) infusion. F, Sample rastergram showing typical 
aNASh MSN response pattern following ICV THC (1µg/µl) and nor-BNI (10µg/µl) infusion. 
 
3.3.7  THC produces differential changes in the power of high-frequency -
oscillations  
In the above described studies, LFPs were recorded concurrently with single-unit activity. The 
signal was divided into bins of 2 seconds and 410 different frequency values. An analysis was 
performed to determine the power each frequency had on the signal. ANOVA tests were 
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conducted on delta, theta, alpha, beta, low-frequency gamma, and high-frequency gamma 
oscillations. Delta, theta, alpha showed no main effect of treatment. A sample spectrograph of an 
aNASh LFP of high-frequency -oscillations recording is shown in Figure 3.7A. ANOVA 
comparing the power of beta (F(2,35) = 7.857, p = .002), low-frequency -oscillations (F(2,35) = 
4.899, p = .013; Figure 3.7B), high-frequency -oscillations (F(2,35) = 3.963, p = .028; Figure 
3.7B) between treatment groups revealed a significant main effect of treatment. Post-hoc 
analyses revealed that the change in power of beta and low-frequency -oscillations between rats 
treated with ICV THC and vehicle were not significantly different (p > .05). Rats receiving ICV 
THC + Cyprodime, however, showed significantly increased power of beta (p = .001) and low-
frequency -oscillations (p = .015) compared to THC alone but not vehicle. Rats receiving ICV 
THC, however, showed significantly increased power of high-frequency -oscillations relative to 
VEH controls (p = .010; Figure 3.7B) or rats treated with ICV THC + CYP (p = .045; Figure 
3.7B). The VEH group also did not differ significantly from the ICV THC + CYP group (p > .05; 
Figure 3.7B). THC, therefore, increased the power of high-frequency -oscillations in the 
aNASh and this effect was reversed by co-treatment with the MOR antagonist.  
 
Next, we ran an analysis on pNASh LFPs. Delta, theta, alpha, and beta showed no main effect of 
treatment.  A sample spectrograph of high-frequency gamma of pNASh LFP is shown in Figure 
3.7C. ANOVA of low-frequency -oscillations (F(2,38) = 5.520, p = .008) and high-frequency -
oscillations (F(2,38) = 5.130, p = .011; Figure 3.7D), however, revealed a main effect of 
treatment. Post-hoc analyses revealed that rats treated with THC+ NorBNI showed significantly 
increased power of low-frequency -oscillations versus THC alone but not vehicle. THC 
treatment significantly decreased the power of high-frequency -oscillations relative to VEH 
controls (p = .004; Figure 3.6D) or rats treated with ICV THC + Nor-BNI (p = .019; Figure 
3.7D). Rats treated with ICV vehicle did not differ significantly from rats treated with ICV THC 
+ Nor-BNI (p > .05; Figure 3.6D). Thus, in direct contrast to the anterior NASh, pNASh THC 
decreased the power of high-frequency -oscillations, through a KOR-dependent signaling 
mechanism. 
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Figure 3.7 Effect of ICV THC on the power of high-frequency gamma oscillations in the 
local field potential signal in the NASh. A, Sample spectrograph showing typical high-
frequency -oscillations in the pNASh following ICV infusion of THC B, ICV THC significantly 
decreases the power of high-frequency -oscillations in the pNASh. * = p < .05 from the other 
two groups. C, Sample spectrograph showing typical high-frequency -oscillations in the aNASh 
following ICV infusion of THC D, ICV THC significantly increases the power of high-frequency 
-oscillations in the aNASh 
 
3.4 DISCUSSION  
The nucleus accumbens serves as a critical neural nexus point for the integration of affective 
information from numerous extrinsic inputs, including the ventral tegmental area (VTA), 
amygdala, ventral hippocampus (vHIPP) and prefrontal cortex (PFC). In addition, THC has been 
shown to strongly modulate intra-NAc signaling from these regions, including DAergic signals 
from the VTA (Cheer, 2004; Morra, Glick, & Cheer, 2010; Morra, Glick, & Cheer, 2012; Oleson 
& Cheer, 2012) and glutamatergic signals from the PFC and vHIPP (Loureiro et al., 2016a; Pistis 
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et al., 2002; Rigucci et al., 2018). Previously, we and others have reported that THC directly within 
the NAc can strongly modulate mesolimbic DAergic activity and NAc neuronal activity states 
(Cheer, 2004; Fitoussi et al., 2018; Morra et al., 2012; Oleson & Cheer, 2012). In addition, THC 
has been shown to directly activate VTA DA neurons (French, 1997). Nevertheless, the 
mechanisms by which THC may produce bivalent, reward and aversion effects within the NAc 
has not previously been characterized.  
 
In the present study, we demonstrate not only that THC produces bivalent effects on reward and 
aversion processing, but identify anatomically, pharmacologically and neuronally dissociable 
mechanisms, directly in the in the anterior vs. posterior NASh that are responsible for these effects. 
We report that intra-NASh infusions of THC produced robust µOR-dependent reward effects 
selectively in the aNASh but produced κOR-dependent aversive effects in pNASh. In addition, 
intra-aNASh THC selectively potentiated morphine-related reward salience but not natural, 
sucrose reward salience. In contrast, intra-pNASh THC reduced social motivation and social 
memory processing, without influencing morphine-related reward processing. Finally, we found 
that ICV infusions of THC produced a predominant decrease in MSN activity, consistent with an 
accumbal reward signature (Carlezon & Thomas, 2009). In direct contrast, THC in the pNASh 
induced a significant increase in MSN neuronal activity with a concomitant decrease in high-
frequency -oscillations. Together, these data characterize the critical functional differences in the 
NASh related to THC modulation of affective processing and demonstrate that distinct OR 
substrates are responsible for these seemingly contradictory effects.  
 
The difference in OR function between the aNASh and the pNASh is not fully understood but 
previous studies have similarly suggested differential effects of these OR subtypes on DA-
mediated phenomena. For example, NASh activation of MORs stimulates DA release while KOR 
activation decreases DA release (Di Chiara & Imperato, 1988). Since DA transmission in the 
NASh is strongly linked to both motivational processing (Ikemoto & Panksepp, 1999) and 
addiction behaviours (Di Chiara et al., 2004; Oleson & Cheer, 2012), differential changes in DA 
release caused by stimulation of distinct NAc OR substrates could potentially underlie these 
bivalent affective phenomena. Previous studies have demonstrated the ability of cannabinoids to 
regulate DA release (Cheer, 2004; Fadda et al., 2006; Kuepper et al., 2010) and enhanced phasic 
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DA release by drugs of abuse is regulated by cannabinoid receptor signaling (Cheer et al., 2007). 
Furthermore, more recent studies have suggested unique circuitry between so-called hedonic 
hotspots in the NASh and a second hedonic hotspot localized in the ventral pallidum (VP). 
Simultaneous activation of both hotspots was necessary to produce “liking” reactions to sucrose 
(Smith & Berridge, 2007). This may suggest that the NASh and the VP cooperate to produce a 
unique, isolated hedonic circuit which can enhance the salience of reward. Future studies are 
required to examine if THC-induced changes in affective processing may similarly depend on 
NAc-VP functional interactions and potential DA signaling alterations. 
 
Clinical and pre-clinical studies have demonstrated biphasic effects of THC on reward and 
aversion processing (Chen et al., 1991; Lepore et al., 1995; Parker & Gillies, 1995). For example, 
strain-dependent differences in sensitivity to the rewarding or aversive stimulus properties of THC 
has been demonstrated in rodents (Parker and Gillies, 1995). In humans, THC exposure produces 
differential rewarding or aversive effects via modulation of striatal activity states and can disrupt 
emotional processing (Bossong et al., 2013, 2015; Englund et al., 2013; Freeman et al., 2015). 
Like many drugs of abuse, THC elicits striatal DA release (Bossong et al., 2015) and can reduce 
limbic network activity when processing negative emotional stimuli (Bossong et al., 2013). THC, 
however, also causes paranoia, anxiety and negative mood (Englund et al., 2013; Freeman et al., 
2015) which increases with dose (Childs et al., 2017). The present findings suggest that relative 
sensitivity to the motivational properties of THC may depend upon distinct effects of THC within 
anterior vs. posterior NAc regions via dissociable OR signaling mechanisms. However, future 
studies are required to determine if similar regional differences in the ventral striatum in humans 
may similarly underlie the bivalent affective properties of THC.  
 
The cannabinoid and opioid receptor systems functionally interact during the processing of 
motivational behaviours (Ahmad et al., 2013; Pickel et al., 2004; Zimmer et al., 2001). For 
example, systemic THC administration has been shown to increase heroin self-administration in 
rats (Solinas et al., 2005) and intra-NAc CB1 receptor blockade has been shown to attenuate 
morphine self-administration (Caillé & Parsons, 2006). Consistent with these reports, the present 
study identifies the anterior NASh region as a local accumbal zone critical for modulating opioid-
related reward salience. Beyond the NAc, we have previously reported that intra-vHIPP CB1R 
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activation strongly increases the reward salience of morphine (Loureiro et al., 2016b). In addition, 
CB1R activation in the PFC was shown to switch the hedonic valence of systemic or intra-VTA 
morphine from rewarding to aversive, through dissociable OR vs. OR-dependent receptor 
mechanisms, directly in the VTA (Ahmad et al., 2013). Interestingly, intra-basolateral amygdala 
(BLA) activation or blockade of CB1R transmission has been shown to switch morphine reward 
behaviours into aversion effects and potentiate the reward salience of sub-threshold morphine, via 
functional modulation of MSN neuronal states in the NAc (Ahmad et al., 2017). Thus, inhibition 
of CB1R signaling in the BLA with an antagonist of CB1R, was shown to potentiate the rewarding 
effects of morphine by causing inhibition of NASh MSN activity states. The present study reveals 
a novel, THC-mediated mechanism directly in the aNASh, that similarly potentiates opioid reward 
salience via inhibition of MSN neuronal activity. Thus, the relative activity levels of NAc MSN 
neuronal populations appears to be a critical mechanism regulating not only the motivational 
valence of THC itself, but also in the interaction of CB1R signaling with the processing of opioid-
related reward or aversion behaviours.  
 
Mesolimbic LFP signals are closely linked to the activity of individual neurons and implicated in 
motivation, drug addiction and psychosis (Cohen et al., 2009; Ge et al., 2018; Uhlhaas, Haenschel, 
Nikolić, & Singer, 2008). More specifically, -oscillations have been implicated in sensory 
integration, associative learning and cognition (Uhlhaas et al., 2008).  For example, previous 
studies have demonstrated that local firing activity of individual neurons is mediated by regionally 
distinct changes in -oscillations in the ventral striatum of rats during reward processing 
(Kalenscher et al., 2010) and there is increased striatal -oscillation activity immediately following 
associative reward delivery (van der Meer & Redish, 2009). The role of -oscillations in striatal 
reward processing is also demonstrated in humans during the processing of monetary rewards or 
losses, which are correlated with distinct -oscillation patterns in the NAc, suggesting that -
oscillation patterns within the striatum may serve as a gating mechanism for the relative encoding 
of rewarding or aversive valences during motivated behaviours (Cohen et al., 2009). The present 
findings reveal for the first time that striatal -oscillation patterns are similarly linked to THC-
dependent affective processing and suggest that THC-induced reward states are associated with 
potentiated -oscillations while aversive states are linked to inhibition of these oscillatory patterns, 
within anterior vs. posterior accumbal zones. 
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Beyond signaling reward or aversion states, changes in -oscillation states have been linked to the 
psychotomimetic effects of THC. For example, THC exposure induces strong dysregulation in -
oscillation states similar to those observed in schizophrenia (Cortes-Briones et al., 2015; Nottage 
et al., 2015; Skosnik, Krishnan, Aydt, Kuhlenshmidt, & O’Donnell, 2006; Y. Sun et al., 2011). 
Due to the increasing evidence of links between THC exposure and neuropsychiatric side-effects 
(Kuepper et al., 2011; Radhakrishnan, Wilkinson, & D’Souza, 2014), the present findings have 
important implications for how THC may lead to disturbances in emotional regulation via -
oscillation alterations. In terms of drug-related effects, previous studies have demonstrated that 
specific patterns of -oscillations within the NAc were present during aversive opioid withdrawal 
states (Dejean et al., 2017), suggesting a link between opioid-related aversion signals and striatal 
-oscillation disturbances. Thus, altered -oscillation states may be critical biomarkers for striatal-
dependent processing of rewarding or aversive motivational states and THC modulation of 
cannabinoid receptor signaling may serve to differentially control reward or aversion processing 
in distinct anterior vs. posterior regions of the NAc. 
 
In summary, the results of the present study reveal several novel mechanisms to account for how 
THC differentially modulates mesolimbic activity states and bivalent affective processing via 
interactions with the opioid receptor system. In addition, these findings have important 
implications for understanding how the effects of THC in anatomically distinct regions of the 
NASh may underlie the neuropsychiatric side-effects of cannabis, including its dependence-
producing properties and psychotomimetic side-effects. 
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CHAPTER 4 
 
4 9-tetrahydrocannabinol (THC) Regulates Memory, Anxiety and 
Sensorimotor Gating via Dissociable Modulation of the Wnt and mTOR 
Signaling Pathways in the Nucleus Accumbens Shell 
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4.1 INTRODUCTION 
Acute and neurodevelopmental exposure to -9-tetrahydrocannabinol (THC), the primary 
psychoactive compound in cannabis, is associated with psychotomimetic side-effects and an 
increased risk of serious neuropsychiatric disorders, such as schizophrenia. Schizophrenia is a 
complex and devastating disorder characterized by disturbances in emotional salience attribution 
(Katthagen et al., 2016; Palaniyappan, Simmonite, White, Liddle, & Liddle, 2013), deficits in 
neurocognitive sensory filtering such as paired-pulse inhibition and facilitation deficits (Winton-
Brown et al., 2015; Wynn et al., 2004), abnormalities in memory formation (Behrendt, 2016; 
Paz-Alonso et al., 2013) and heightened anxiety and paranoia (American Psychological 
Association, 2013; Buonocore et al., 2018; Malcolm, Picchioni, & Ellett, 2015; Morrison & 
Cohen, 2014; Tandon et al., 2013). Importantly, clinical and pre-clinical evidence has 
demonstrated that exposure to THC is capable of producing all of these psychiatric 
endophenotypes via its modulatory influence on mesocorticolimbic dopamine (DA) transmission 
and associated molecular signaling pathways (Bossong et al., 2015; Radhakrishnan et al., 2014; 
Renard et al., 2017). For example, acute or neurodevelopmental exposure to chronic THC has 
been shown to induce long-term hyperactivation of subcortical ventral tegmental area (VTA) 
mesolimbic DA activity and associated adaptations in cortical molecular signaling cascades 
linked to disorders like schizophrenia, including the glycogen-synthase-kinase-3 (GSK3), protein 
kinase B (Akt), mammalian target of rapamycin (mTOR) and p70-S6-Kinase (p70S6K) 
pathways (Fitoussi et al., 2018; Renard et al., 2017).  
 
The ventral striatum (nucleus accumbens; NAc) is a brain region that is critically involved in the 
neuropathological phenotypes associated with schizophrenia and anxiety-related disorders (Bahi 
& Dreyer, 2018; Holt et al., 2005; Kim et al., 2008; McCollum & Roberts, 2015; Morris et al., 
2012) and serves as an important target for the psychotropic effects of THC. For example, 
human imaging studies have shown that THC exposure strongly modulates activity states in the 
ventral striatum where it has been shown to disrupt cognitive performance (Bhattacharyya et al., 
2012; Bhattacharyya et al., 2009; Fusar-Poli et al., 2009). In pre-clinical studies, acute THC has 
been shown to act within the NAc to induce hyperactivity in VTA DA neurons by reducing 
inhibitory GABAergic inputs to the DA system, and concomitantly potentiate the emotional 
salience of normally non-salient associative fear-memory cues (Fitoussi et al., 2018). 
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In terms of anxiety-related processing, previous research has established that THC produces 
seemingly contradictory effects. For example, cannabis users may report euphoria, feelings of 
well-being and joviality (Osborne & Fogel, 2008); and THC has been demonstrated to be 
anxiolytic at low doses (Berrendero & Maldonado, 2002; Rubino et al., 2007). Conversely, THC 
also has dependence-producing properties (Gardner, 2002; Tanda & Goldberg, 2003; Zangen et 
al., 2006), can modulate associative fear memory processing (Fitoussi et al., 2018; Klumpers et 
al., 2012) and produces anxiogenic effects at higher doses (Bhattacharyya et al., 2010; Crippa et 
al., 2009; Englund et al., 2013). Finally, THC has been previously demonstrated to impair 
recognition memory (Kasten, Zhang, & Boehm, 2017; Swartzwelder et al., 2012), similar to 
memory impairments observed in schizophrenia patients (Forbes, Carrick, McIntosh, & Lawrie, 
2009; Grimes, Zanjani, & Zakzanis, 2017; Herbener, 2008; Herbener, Rosen, Khine, & Sweeney, 
2007).  
 
At the molecular level, substantial evidence implicates a role for the wingless/ integrated (Wnt) 
signaling cascade (i.e. protein kinase B [Akt], glycogen synthase kinase-3 [GSK-3] and -
catenin) and the mammalian target of rapamycin (mTOR) pathway (i.e. p70S6 kinase [p70S6K], 
protein kinase B [Akt] and mTORc) directly within the limbic system, during the acquisition, 
consolidation, retrieval, and reconsolidation of associative fear memory (Gafford, Parsons, & 
Helmstetter, 2013; Jarome, Perez, Hauser, Hatch, & Lubin, 2018; Jobim et al., 2012; Maguschak 
& Ressler, 2011; Xu et al., 2015). For example, disruption of Wnt signalling, specifically -
catenin, in the amygdala, prevented consolidation of fear-memory (Maguschak & Ressler, 2011). 
Additionally, inhibition of mTOR in the amygdala or hippocampus impaired the formation and 
reconsolidation of avoidance memory (Jobim et al., 2012). Furthermore, activation of CB1 
receptors, the primary target for THC, can functionally modulate these signalling pathways and 
their phosphorylation states (Korem, Lange, Hillard, & Akirav, 2017; Puighermanal et al., 2013) 
suggesting that they may underlie the influence THC has on fear and anxiety-related behaviours. 
 
In the present study, we used a combination of pre-clinical behavioural assays targeting cognitive 
and affective endophenotypes associated with schizophrenia-related deficits in rats, in 
combination with anatomically localized molecular signalling analyses to examine the effects of 
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direct microinfusions of THC on Wnt and mTOR signalling proteins, associative fear memory, 
prepulse inhibition (PPI) and prepulse facilitation (PPF), object recognition memory, and 
anxiety. We report that THC infused in the posterior region of the NAc shell (pNASh) 
potentiates the formation of associative fear memory to sub-threshold footshock, impairs 
PPI/PPF, produces anxiety and disrupts object recognition memory through a GSK-3 dependent 
signaling mechanism. Conversely, THC infused into the anterior NASh (aNASh), blocks the 
formation of associative fear memory to supra-threshold footshock and reduces anxiety. When 
co-administered with an Akt activator, the formation of associative fear memory returned, the 
formation of object recognition memory was disrupted, and anxiety was further reduced. These 
findings reveal several novel and dissociable mechanisms for the psychotropic effects of THC 
within the NASh, mediated through distinct anatomical and molecular substrates. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Animals and Surgery 
Male Sprague Dawley rats (300 to 350 g; Charles River, Quebec, Canada) were used in 
compliance with the Canadian Council for Animal Care and institutional guidelines. Rats were 
housed under controlled conditions (12-hour light/dark cycle and food/water access ad libitum). 
Rats were anesthetized with a mixture of ketamine (80 mg/ml) and xylazine (6 mg/ml) and 
placed in a stereotaxic device. Stainless steel guide cannula (22- gauge; PlasticsOne) were 
implanted bilaterally into either the aNASH at the following coordinates (Paxinos & Watson, 
2005): AP: +2.5 mm from bregma, L: ±2.6 mm, DV: -7.4 mm from the dural surface, or the 
pNASH at the following coordinates: anteroposterior (AP): +1.5 mm from bregma, lateral 
(LAT): ±2.6 mm, dorsoventral (DV): -7.4 mm from the dural surface. Guide cannulae were held 
in place using jeweler’s screws and dental acrylic cement. After completion of behavioural 
experiments, rats received an overdose of pentobarbital (240 mg/kg, i.p.) and were perfused with 
isotonic saline followed by 10% formalin. Brains were extracted and post-fixed 24 h before 
being placed in a 25% formalin-sucrose solution for one week. Brains were sliced (60 μm) using 
a cryostat and stained with Cresyl violet. Injector tips placements were localized using a light 
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microscope. Rats with cannula placements found outside the anatomical boundaries of the NASh 
were excluded from data analysis. 
 
4.2.2 Drug Treatment and Administration 
The following drugs were used during behavioural experiments or protein analysis: 9-
tetrahydrocannabinol (THC; 100 ng/0.5 µl; Tocris Bioscience), the selective GSK3 inhibitor 
SB216763 (300 ng/ 0.5µl; Tocris Bioscience) and the AKT phosphorylation promoter SC-79 
(10nM/0.5µl; Tocris Bioscience). The dosage of SB216763 was based on a previously published 
intra-NA effective dose (Wickens, Quartarone, & Beninger, 2016). THC was shipped in ethanol 
then dissolved in cremaphor. The ethanol was evaporated with nitrogen gas. The solution was 
then diluted with saline to the desired concentration. SB216763 was dissolved in DMSO and 
then diluted in PBS for a final 1% DMSO in PBS. SC-79 was dissolved in DMSO and then 
diluted in PBS for a final 20% DMSO in PBS. Intra-NASh microinfusions were performed 
immediately prior to each conditioning session. A total volume of 0.5 µl per hemisphere was 
delivered via a 28-gauge microinfusion injector over a period of 1 min. Microinjectors were left 
in place for an additional 1 min to ensure adequate diffusion from the tip. The intra-cranial dose 
selections for the above compounds were based upon our previously published or piloted dose-
response curves using these compounds (Ahmad et al., 2013; Norris et al., 2016) which 
demonstrated maximal behavioural efficacy and the absence of non-specific behavioural side 
effects. 
 
4.2.3 Protein Extraction and Western Blots 
To examine the potential localized effects of intra-NAc THC on select molecular signaling 
pathways (described below), a subset of experimental rats was given intra-aNASh infusions of 
THC (100 ng/ 0.5µl per side; n= 8) or vehicle (n = 8) or intra-pNASH infusions of THC (100 ng/ 
0.5µl per side; n= 8) or vehicle (n = 8). Ten minutes later, the rats were anesthetized with 
pentobarbitol and their brains were removed and rapidly frozen. The section of the brains 
containing the NAc were cut using a cryostat to obtain coronal sections (60 µm), from which 
bilateral micropunches were taken from around the infusion site within the NASh. The Western 
blotting procedure was conducted as described previously (Lyons et al., 2013). Protein levels 
were measured using the bicinchoninic acid (BCA) assay. The sample solutions were there 
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diluted with buffer to make all concentration equals and all wells were loaded with 60µl. Run 
time and transfer time were adjusted based on molecular weight. Primary antibody dilutions were 
as follows: α-tubulin (1:120000; Sigma-Aldrich), phosphorylated GSK-3α/β ser21/9 (p-GSK-
3α/β; 1:1000; Cell Signaling Technology), total GSK-3α/β ser21/9 (t-GSK-3α/β; 1:1000; Cell 
Signaling Technology), phosphorylated Akt Ser473 (p-Akt-Ser473; 1:1000; Cell Signaling 
Technology), phosphorylated Akt thr308 (p-Akt-thr308; 1:1000; Cell Signaling Technology), 
total Akt (t-Akt; 1:1000; Cell Signaling Technology), β-catenin (1:10000; Sigma-Aldrich), 
phosphorylated mTOR ser2448 (p-mTOR;1:2000; Cell Signaling Technology), total mTOR (t-
mTOR; 1:2000, Cell Signaling Technology), phosphorylated p70S6K thr389 (p-p70S6K; 
1:1000; Cell Signaling Technology), total p70S6K (t-p70S6K; 1:1000; Cell Signaling 
Technology). Species appropriate secondary antibodies for LICOR imaging were all used at a 
concentration of 1:20,000 (Thermo Scientific). 
 
4.2.4 Olfactory Fear Conditioning 
We used a previously described olfactory fear conditioning paradigm to measure fear memory 
(Draycott et al., 2014; Lauzon et al., 2009; see also Chapter 2). Two distinct environments were 
used. Environment A was a 30” x 30” Plexiglass box with black spots on a white background 
and environment B was a 30” x 30” Plexiglass box with black and white stripes. The designated 
shock environment had a metallic grid shock floor while the designated test environment had a 
smooth grey Plexiglas floor. The environments were assigned as “shock” and “test” in a 
counterbalanced manner such that all rats with “shock” environment A were tested in 
environment B and all rats with “shock” environment B were tested in environment A. On day 1 
(habituation) rats were given sham microinfusions into the NASh and habituated to both 
conditioning environments for 30 min. Footshocks were delivered at an intensity of 0.8 mA, 
which we have previously reported to produce highly robust fear memories, or 0.4 mA, which 
does not produce fear memories (Draycott et al., 2014; Lauzon et al., 2009). On day 2 
(conditioning phase) rats were returned to the room and, immediately prior to being placed in the 
previously assigned “shock” environment, rats received intra-NASh microinfusions of THC 
(100ng/0.5μl); the GSK3 inhibitor SB216763 (300ng /0.5μl) in combination with THC; the 
AKTser473 phosphorylation promoter SC-79 (10nM /0.5μl), in combination with THC. Two 
odours were delivered during conditioning, almond and peppermint. One odour was presented 
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with a footshock (CS+) and the other was presented in the absence of a footshock (CS-). After 
one minute in the “shock” environment, the CS- odour was presented for 20 sec. Two min later, 
the CS+ odour was presented for 19 sec followed by a 1 sec footshock delivered through the 
shock floor. This cycle was repeated 5 times. On day 3 (test phase) rats were placed in the 
previously assigned test environment. They were given 1 min to explore the environment before 
odour presentations began, during which time baseline levels of freezing behaviour were 
recorded. Both CS+ and CS- odours were presented in a fully counterbalanced order for 5 min 
and amounts of time rat’s spent freezing (lack of movement except for respiration) was recorded 
and analyzed with ANY-MAZE™ video software for offline analysis. Fear scores were 
calculated by subtracting the time (s) spent freezing to the CS- from the percent of time (s) spent 
freezing to the CS+. 
 
4.2.5 Pre-pulse Inhibition and Facilitation  
Pre-pulse modulation of the Acoustic Startle Response (ASR) was conducted in sound-
attenuating startle chambers (LE116, Panlab, Spain) using the StartFear system and STARTLE 
software modules (PACKWIN-CSST, PACKWIN V2.0, Spain), which enable the recording and 
analysis of animal movement and startle response through a high sensitivity Weight Transducer 
system. Rats were placed into large, perforated Plexiglass tubes, set on the motion-sensitive 
platform in the sound attenuating chamber. Rats acclimated to the startle chambers for 5 
minutes/day with background noise (white noise; 68 dB) over 2 days. During the final 
acclimation session, rats underwent an input/output (I/O) function test consisting of 11 
increasing startle pulses (from 70 to 120 dB, 5 dB increments) to determine the appropriate gain 
setting for each individual rat. The testing procedure consisted of the following phases: the 
acclimation phase, a habituation phase (Block 1), prepulse inhibition (PPI) measurement (Block 
2), and prepulse facilitation (PPF) measurement (Block 3). White background noise (68 dB) was 
ubiquitously presented during all phases of the experiment. During Block 1, 10 pulse alone trials 
(110 dB white noise, 20 ms duration) were randomly delivered at 15–20 s inter-trial intervals 
(ITIs). Block 2 consisted of 10 different trials presented 10 times each in a randomized order at 
15–20 s intervals: 10 pulse-alone trials, and 10 of each of the three different prepulse-pulse trial 
types (72, 76, 80 dB) with interstimulus intervals (ISI) of 30, 100 and 800 ms. Whether PPF or 
PPI is induced seems to be best predicted by ISI and prepulse type. Very short (<10-15 ms) or 
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very long (>1000 ms) ISIs tend to be the most effective at inducing PPF. Block 3 consisted of 10 
different trials presented 10 times each in a randomized order at 15–20 s intervals: 10 pulse-
alone trials, and 10 of each of the three different prepulse-pulse trial types (72, 76, 80 dB) with 
interstimulus intervals of 1000, 1500 and 2000 ms. PPF intervals times were based on previous 
human testing on schizophrenic patients (Wynn et al., 2004). Pulse-alone trials consisted of a 
startle stimulus-only presentation, whereas prepulse-pulse trials consisted of the presentation of a 
weaker non-startling prepulse (white noise, 20 ms duration) before the interstimulus interval and 
startling stimulus. Blocks 2 and 3 were conducted on separate days and were each preceded by 
Block 1. PPI was calculated for each animal and each trial condition as PPI (%) = (1 − average 
startle amplitude to pulse with prepulse/average startle amplitude to pulse only) × 100. The final 
number of rats in each group was as follows: Intra-anterior NASh VEH group 
(anterior/VEH), n = 8; Intra-anterior NASh THC group (anterior/THC), n = 9; Intra-posterior 
NASh VEH group (posterior/VEH), n = 9; Intra-posterior NASh THC group 
(posterior/THC), n = 9.  
  
4.2.6 Novel Object Recognition 
Rats were tested using the object recognition task as described previously (Renard et al., 2017). 
This task evaluates the ability of the rat to discriminate between the familiarity of previously 
encountered objects; normal rats typically spend more time exploring a novel object than a 
familiar object. The test sessions consisted of two 3-min trials. During the first trial (T1 
acquisition trial), each rat was placed in the center of an arena containing two identical objects 
placed in the far corners 15 cm from the side wall. After a delay of 60 min during which the rat 
was returned to its cage, and both objects were replaced (one by an identical copy, the other by a 
novel object in the same location), the rat was returned to the arena for the second trial (T2 test 
trial). Between rats, both the role (familiar or novel object) and the relative position of the two 
objects were randomly counterbalanced. Object exploration was considered when the head of the 
rat was facing the object, or the rat was touching or sniffing the object. Times spent in 
exploration were videotaped with a video-tracking system (ANY-maze; Stoelting) and analyzed 
by an experimenter. Exploration times were recorded and used to calculate discrimination index 
[time spent with novel object/total time exploring both objects] *100. 
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4.2.7 Elevated Plus Maze 
This task seeks to evaluate the anxiety levels of the animal. The apparatus consists of four arms: 
two open and two enclosed with walls. The testing session consisted of 2 minutes of acquisition 
followed by 8 min of testing. The rats were infused with one of the testing drugs then placed in 
apparatus and allowed to freely explore. Time spent in the open and closed arms was recorded by 
with video-tracking software (ANY-Maze; Stoelting) and analysed by an experimenter. 
 
4.3 RESULTS 
4.3.1 Histological Analysis 
Histological analysis revealed injector placements localized within the anatomical boundaries of 
the shell subdivision of the NASh. Sample NASh microinfusion locations and schematic 
illustration of several experimental groups across the anterior-posterior axis of the NASh are 
shown in Figure 4.1. 
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Figure 4.1 Histological analysis of intra-NASh microinjection sites. A, Microphotograph of 
representative injector placement within the anterior portion of the nucleus accumbens shell. B, 
Schematic representation of select intra-anterior-NASh injector locations;  = 100 ng THC 
group,  = 100 ng THC + 10 nM SC-79. C, Microphotograph of representative intra-anterior-
NASh bilateral cannulae placements. D, Microphotograph of representative injector placement 
within the posterior portion of the nucleus accumbens shell. E, Schematic representation of 
select intra-posterior-NASh injector locations;  = 100 ng THC group,  = 100 ng THC + 300 ng 
SB216763. F, Microphotograph of representative intra-posterior-NASh bilateral cannulae 
placements. 
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4.3.2  Intra-aNASh THC infusions produce decreases in phosphorylated 
protein levels of Akt Ser473 and mTOR ser2448 
 We first examined the potential localized effects of intra-aNASH THC (100 ng/ 0.5 µl) 
exposure on the expression levels of the Akt and mTOR signalling pathways (-catenin, GSK-
3/, Akt, p70S6K and mTOR) as previous studies from our lab have demonstrated that THC 
exposure can profoundly alter their activity and modulate THC-related affective and cognitive 
side-effects in neural regions such as the prefrontal cortex (Renard et al., 2017). In addition, 
previous studies have implicated these specific molecular pathways as being critical for striatal-
mediated cognitive and affective processing phenomena (Bergeron, Chagniel, Bureau, 
Massicotte, & Cyr, 2014; Cuesta et al., 2017; Ding et al., 2013; Luo et al., 2016; Xu et al., 2015). 
In previously reported dose-response analyses, we have identified this dose of intra-NAc THC 
(100 ng) as being pharmacologically and behaviourally effective for localized intracranial 
infusions (Norris et al., 2016, Fitoussi et al., 2018). In the present series of studies, we separately 
analyzed posterior vs. anterior NAc regions to determine if anatomically distinct effects of THC 
may be identifiable between these regions. A simplified diagram of these molecular signaling 
pathways and their known mechanistic downstream neurophysiological and neuropsychiatric 
effects is presented in Figure 4.2. 
 
THC in the Anterior NASh selectively decreases phosphorylation states of Akt and 
mTOR  
First, we examined any potential changes in protein expression comparing rats who received 
intra-aNASh THC (100 ng/ 0.5µl) vs. vehicle. Western blot analysis revealed a significant 
reduction in phosphorylated expression levels of Akt-Ser473 (pAktSer473; t(6) = 2.789, p = .032) 
and the ratio between pAktSer473 and total Akt (tAkt; t(6) = 2.545, p = .044) but not tAkt, 
phosphorylated Akt-Thr308 (pAktThr308) or the ratio between pAktThr308 and tAkt (p > .05; 
Figure 4.3A). There was also a significant reduction in phosphorylated mTOR (pmTOR) vs. 
vehicle (t(6) = 2.718, p = .035;) and the ratio between total tmTOR (tmTOR) and pmTOR (t(6) = 
2.744, p = .034) but no significant change in levels of tmTOR (p > .05; Figure 4.3C). There was 
no significant change in phosphorylated GSK-3 (pGSK3), total GSK-3 (tGSK3), the ratio 
between pGSK3 and tGSK3 (Figure 4.3E), phosphorylated p70S6K (p-p70S6K), total p70S6K 
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or the ratio between p-p70S6K and t- p70S6K (data not shown); or -catenin (p > .05; Figure 
4.3G). 
 
THC in the Posterior NASh selectively decreases phosphorylation states of GSK3 and 
increases -catenin levels 
Next, we examined any potential changes in protein expression levels between rats who received 
intra-pNASh THC (100 ng/ 0.5µl) or vehicle. Western blot analysis revealed a significant 
reduction in pGSK (t(13) = 2.933, p = .012) and the ratio between pGSK and tGSK (t(13) = 
2.493, p = .027) but not tGSK, pGSK, tGSK or the ratio between pGSK and tGSK (p > 
.05; Figure 4.3F). There was also a significant increase in -catenin vs. vehicle (t(5) = -2.674, p = 
.044; Figure 4.3H). There was no significant change in pAktSer473, pAktThr308, tAKT, the 
ratio between pAktSer473 and tAkt, the ratio between pAktThr308 and tAkt (Figure 4.3B), 
phosphorylated p70S6K (p-p70S6K), total p70S6K (t- p70S6K) or the ratio between p-p70S6K 
and t- p70S6K (data not shown), pmTOR, tmTOR, or the ratio between pmTOR and tmTOR (p 
> .05; Figure 4.3D).  
Thus, these findings demonstrate several critical dissociations in terms of THC-dependent 
modulation of the GSK3-Wnt vs. mTOR signaling pathways, via anatomically localized effects 
in the anterior vs. posterior NAc sub-regions. We next performed a battery of behavioural assays 
(see methods) to further explore the potential mechanistic roles for these effects on affective and 
cognitive processing phenomena. 
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Figure 4.2 Proposed CB1 signaling pathways. pAkt Ser473 to mTOR pathway, known to be 
involved in cellular remodeling and GSK3 to -catenin Wnt pathway, involved in gene 
transcription 
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Figure 4.3 Effects of intra-NASh THC on signaling proteins. A, Intra-aNASh THC reduces 
Ser473 pAkt and the ratio of Ser473 pAkt to tAkt * = p < .05 B, Intra-pNASh THC has no effect 
on Akt levels C, Intra-aNASh THC reduces pmTOR and the ratio of pmTOR to tmTOR * = p < 
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.05. D, Intra-pNASh THC has no effect on mTOR levels E, Intra-aNASh THC has no effect on 
GSK3 levels. F, Intra-pNASh THC reduces pGSK3 and the ratio of pGSK3 to tGSK3 * = p < 
.05. G, Intra-aNASh THC has no effect on GSK3 levels. H, Intra-pNASH THC increases -
catenin * = p < .05. I, Intra-aNASh THC has no effect on -catenin levels. 
 
4.3.3  Intra-NASh THC produces anatomically dissociable effects on 
associative fear memory formation through distinct GSK3 vs. Akt 
signaling mechanisms 
Given previous evidence demonstrating functional differences in fear processing in the anterior 
vs. posterior NASh regions (Castro, Terry, & Berridge, 2016) and the ability of THC to modulate 
the affective salience of fear memory-related conditioning cues (Fitoussi et al., 2018; Klumpers 
et al., 2012), we next examined the potential effects of THC (100ng/ 0.5 µg) in the aNASh vs. 
pNASH during the encoding of associative olfactory fear memory [see methods]. In these 
studies, we examined the potential effects of aNASh vs. pNASh exposure on modulating the 
salience of fear-related memory encoding using both a sub-threshold footshock cue or a supra-
threshold conditioning cue, as previously described (Fitoussi et al., 2018). Given our previous 
findings (Figure 4.3) showing selective effects on GSK3 vs. Akt phosphorylation states in the 
posterior vs. anterior NASh, we further explored the potential roles of these signaling pathways 
by challenging the effects of aNASh or pNASh THC with co-administration of a selective Akt 
phosphorylation activator (SC-79) or a GSK3 inhibitor (SB216763: effective at inhibiting both 
GSK-3α and GSK-3β isoforms), respectively. Importantly, since intracellular GSK3 levels are 
negatively regulated by phosphorylation state (i.e. GSK3 phosphorylation results in lower active 
amounts of GSK3), our finding of reduced pGSK3 (Figure 4.3F) would predict higher GSK3 
activity levels. Thus, we chose a selective inhibitor of active GSK3 to challenge this effect 
behaviourally. We selected doses of SC-79 or SB216763 based on dose-response pilot studies in 
our laboratory and on previously published work reporting effective doses within this range for 
in vivo behavioural intracranial infusions in the NAc (Wickens et al., 2017).  
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First, we examined the potential effects of intra-pNASh THC on the formation of a sub or supra-
threshold associative fear memory. For supra-threshold fear conditioning, intra-pNASh THC (n 
= 7) had no effect on freezing behaviours relative to VEH control rats (n = 7; t(12) = -.323, p > 
.05). In contrast, for sub-threshold fear conditioning, One-way ANOVA comparing groups 
revealed a main effect of treatment on freezing scores (F(2,18) = 16.519, p < .001; Figure 4.4A).  
Post-hoc tests revealed that rats receiving THC (100 ng/ 0.5 µl; n = 7) demonstrated significantly 
greater freezing relative to VEH controls (n = 6; p = .001). In addition, co-administration with 
the selective GSK3 inhibitor, SB216763 (300 ng/ 0.5 µl) reversed the effects of THC on 
potentiation of sub-threshold fear memory formation, as this group did not show increased 
freezing relative to VEH controls (p > .05; Figure 4.4A).  Thus, THC in the pNASh was able to 
potentiate the salience of normally non-salient fear conditioning memories through a GSK3-
dependent mechanism, while having no apparent effect on the encoding of supra-threshold 
associative fear memory. 
 
Next, we examined the potential effects of intra-aNASh THC on the formation of sub or supra-
threshold associative fear memory. For sub-threshold fear conditioning, intra-aNASh THC (n = 
6) had no effect on freezing behaviours relative to VEH control rats (n = 7; t(11) = .235, p > .05). 
In contrast, for supra-threshold fear conditioning, One-way ANOVA comparing groups revealed 
a main effect of treatment on freezing scores (F(2,18) = 11.111, p = .001; Figure 4.4A).  Post-hoc 
tests revealed that rats receiving THC (100 ng/ 0.5 µl; n = 7) demonstrated significantly less 
freezing relative to VEH controls (n = 8; p = .004). In addition, co-administration with the Akt 
promotor, SC-79 (10 µM/ 0.5 µl; n = 8) reversed the effects of THC on potentiation of supra-
threshold fear memory formation, as this group did not show decreased freezing relative to VEH 
controls (p > .05; Figure 4.4B).  Thus, THC in the aNASh was able to block the salience of 
normally salient fear conditioning memories by reducing Akt activity, while having no apparent 
effect on the encoding of sub-threshold associative fear memory. 
 
In summary, THC in the anterior vs. posterior NASh differentially regulates the encoding of 
associative fear memories via dissociable GSK3 vs Akt-dependent signaling mechanisms. Intra-
pNASh THC amplifies the emotional salience of normally non-salient fear memory through a 
GSK3-dependent mechanism while having no effect on the encoding of normally supra-
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threshold fear memories. In direct contrast, intra-aNASh THC blocks the formation of normally 
salient associative fear memories by suppressing Akt activity, while having no effect on the 
salience encoding of normally non-salient fear conditioning cues. 
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Figure 4.4 Effects of intra-NASh THC olfactory fear conditioning. A, Olfactory fear 
conditioning difference scores (the difference between the percent of time spent freezing to the 
CS+ and the CS-) for microinfusions into the posterior NASh (+1.5mm from bregma). * = p < 
.05 B, Olfactory fear conditioning difference scores (the difference between the percent of time 
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spent freezing to the CS+ and the CS-) for microinfusions into the anterior NASh (+2.5mm from 
bregma). * = p < .05. Sub = shock of 0.4mA, Supra = shock of 0.8mA. 
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4.3.4 Intra-NASh THC selectively impairs prepulse inhibition and facilitation  
Given the known ability of THC exposure to disrupt sensorimotor and cognitive filtering 
(Bhattacharyya et al., 2012; Bhattacharyya et al., 2010; Morgan et al., 2012, Renard et al., 2016) 
and the previous studies that have implicated the nucleus accumbens in the acoustic startle 
response (Goto, Ueki, Iso, & Morita, 2004; Wan & Swerdlow, 1996), we next examined the 
effects of aNASh or pNASh THC on prepulse inhibition and facilitation behaviours. First to 
ensure that drug treatment had no effect on baseline startle, ANOVA comparing responses to the 
startle pulse alone was conducted and showed no significant difference between groups (F(5,41) = 
1.952, p > .05). Repeated measures ANOVA for intra-pNASH infusions revealed a main effect 
of treatment (F(2,19) = 138.031, p < .001), a main effect of startle condition (interstimulus interval 
and decibel level; F(8,152) = 43.788, p < .001) but no treatment x startle condition interaction 
(F(24,216) = .949, p > .05). Post-hoc tests using Tukey’s HSD to control for multiple comparisons 
revealed that PPI in rats receiving intra-pNASh THC (n = 6) was significantly lower than rats 
receiving intra-pNASh vehicle (n = 8) in the following startle conditions: 76db/ 30ms (p = .001), 
76db/100ms (p = .023),  76db/ 800ms (p = .024), and 80db/100ms (p = .004; Figure 4.5A) and 
was significant lower that rats receiving intra pNASh THC plus SB216763 (n = 8) for the 
following startle conditions: 76db/ 30ms (p = .019), and 80db/100ms (p = .002). Repeated 
measures ANOVA for intra aNASh infusions, testing if there was any difference in PPI between 
vehicle (n = 8), THC (n = 9), and THC + SC-79 (n = 8), revealed a main effect of startle 
condition (F(8,176) = 27.290, p < .001) but no main effect of treatment (F(2,22) = .927, p > .05) or a 
startle x treatment interaction (F(16,176) = .775, p > .05; Figure 4.5B). These data indicate that 
THC in the pNASh but not the aNASh impairs PPI.  
 
Next, repeated measures ANOVA for intra pNASh infusions on PPF data revealed a main effect 
of startle condition (F(8,136) = 12.943, p < .001), treatment (F(5,35) = 3.763, p = .044) and a 
treatment x startle condition interaction (F(16,136) = 3.549, p < .001; Figure 4.5C). Post-hoc tests 
revealed that rats receiving THC (n = 7) differed significantly from rats receiving vehicle (n = 7)  
during the 72db/2000ms (p = .008) and 76db/2000ms conditions (p = .033). Rats receiving THC 
+ SB216763 (n = 6) did not differ significantly from THC treated rats at either 72db/2000ms (p > 
.05) or 76db/2000ms (p > .05), nor VEH controls (p > .05), indicating SB216763 attenuated the 
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effect of THC. Repeated measures ANOVA for intra-aNASh THC revealed a significant main 
effect of startle condition (F(8,144) = 21.720, p < .001), startle x treatment interaction (F(16,144) = 
12.943, p < .001) but no main effect of treatment (F(2,18) = .204, p > .05). Post-hoc tests revealed 
that rats receiving THC (n = 8) did not differ significantly from vehicle (n = 8) during any startle 
condition, rats receiving THC + SC-79 (n = 8) did differ significantly from vehicle during the 
72db/2000ms (p = .038) and 82db/1000ms (p = .001). These data indicate that intra-pNASh THC 
exposure selectively impairs PPF and PPI behaviours through a GSK3 dependent mechanism. In 
contrast, intra-aNASh THC has no effect on PPI measures or PPF in and of itself. However, co-
administering intra-aNASh THC with the Akt activator, SC-79, induces effects similar to those 
of intra-pNASh THC exposure. 
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Figure 4.5 Effects of intra-NASh THC on prepulse inhibition and facilitation. A, Intra-
pNASh THC reduces overall PPI p < .05. B, Intra-aNASh THC has no effect on PPI at any tested 
range. C, Intra-pNASh THC significantly reduces PPF behaviours, which is restored by co-
administration of the GSK3 blocker SB216763. D, Intra-aNASh THC has no effect on PPF in 
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and of itself, but co-administration with the Akt activator (SC-79) induces impairments similar to 
those observed following pNASh THC exposure (p < .05) 
4.3.5  Intra-NASh THC produces opposing effects on object recognition 
memory by altering GSK3 and Akt signalling 
Given previous studies demonstrating that systemically administered THC impairs object 
recognition memory (Kasten et al., 2017; Quinn et al., 2008; Swartzwelder et al., 2012) and the 
established role of the NAc in the processing of object recognition memory (Asif-Malik, Dautan, 
Young, & Gerdjikov, 2017), we next examined the potential effects of intra-NASh THC on a 
novel object recognition task, again comparing anterior vs. posterior regions combined with 
pharmacological targeting of GSK3 or Akt. First, examining THC effects in the pNASh, 
ANOVA comparing the object recognition index between groups revealed a main effect of 
treatment (F(2,18) = 19.011, p < .001). Post-hoc tests revealed that rats receiving intra-pNASh 
THC had significantly impaired object recognition scores relative to VEH controls (100 ng/ 
0.5µg; n’s = 7; p = .038). However, co-administration with the GSK3 inhibitor, SB216763 (300 
ng/ 0.5 µg; n = 7) reversed this effect relative to THC treated rats (p < .001) and resulted in 
significantly greater object recognition scores relative to vehicle controls (p = .008; Figure 6A).  
 
Next, examining THC effects in the aNASh, ANOVA comparing the object recognition index 
between groups, revealed a main effect of treatment (F(2,16) = 9.191, p = .002). Post-hoc tests 
revealed that rats receiving a co-administration of intra-aNASh THC and the Akt promoter SC-
79 (n = 7) had significantly impaired object recognition scores relative to VEH controls (100 ng/ 
0.5µg; n = 6; p = .008) and THC alone (n = 6; p = .004; Figure 6B). Taken together, these data 
suggest that intra-pNASh THC impairs novel object memory through a GSK3 dependent 
mechanism and while intra-aNASh THC has no effect, simultaneously activating AKT produces 
deficits on object memory similar to intra-pNASh THC, consistent with our previously observed 
effects with PPF behaviours. Interestingly, co-administration of THC with a GSK3 inhibitor in 
the pNASh produced a pro-cognitive effect, relative to VEH controls. 
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Figure 4.6 Effects of intra-NASh THC on object recognition memory. A, Intra-pNASh THC 
reduces the discrimination index (the amount of time spent exploring the novel object divided by 
the total exploration time), which is restored above vehicle by co-administration of the GSK3 
blocker SB216763 * = p < .05 compared to Posterior Vehicle, ✟ = p < .05 compared to Posterior 
THC. B, Intra-aNASh THC has no effect on the discrimination index (the amount of time spent 
exploring the novel object divided by the total exploration time) but when THC is co-
administered with the Akt phosphorylation promoter SC-79, the discrimination index is reduced 
* = p < .05 compared to Anterior Vehicle, ✟ = p < .05 compared to Anterior THC. 
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4.3.6  GSK3 blockade reverses the anxiogenic effects pNASh THC while 
AKT activation in the aNASh potentiates THC-induced anxiolysis  
The elevated plus maze is a commonly used test of anxiety and systemically administered THC 
is known to be anxiogenic in this task (Onaivi, Green, & Martin, 1990). We therefore evaluated 
the potential effects of intra-NASh THC on this task, comparing the effects of anterior vs. 
posterior THC and related GSK3 and Akt signaling mechanisms. First, examining the effects of 
intra-pNASh THC, ANOVA on time (s) spent in the closed arms revealed a main effect of 
treatment (F(5,40) = 23.299, p < .001). Post-hoc tests revealed that rats receiving intra-pNASh 
THC (100 ng/ 0.5 µg; n = 8) spent significantly more time in the closed arms compared to 
vehicle (n = 7; p = .012) but rats receiving intra-pNASh THC (100 ng/ 0.5 µg) + SB216763 (300 
ng/ 0.5 µg) spent significantly less time in the closed arms than vehicle (n = 7; p = .005). 
Additionally, rats receiving intra-pNASH THC spent significantly more time in the closed arms 
than rats receiving intra-pNASh THC + SB216763 (p < .001; Figure 4.7A). Next, ANOVA 
testing on time (s) spent in the open arms following infusions into the pNASH, revealed a main 
effect of treatment (F(5,40) = 23.249, p < .001). Post-hoc tests revealed that rats receiving intra-
pNASh THC (100 ng/ 0.5 µg; n = 8) spent significantly less time in the open arms compared to 
vehicle (n = 7; p = .003) but rats receiving intra-pNASh THC (100 ng/ 0.5 µg) + SB216763 (300 
ng/ 0.5 µg) spent significantly more time in the open arms than vehicle (n = 7; p = .029). 
Additionally, rats receiving intra-pNASH THC spent significantly less time in the open arms 
than rats receiving intra-pNASh THC + SB216763 (p < .001; Figure 4.7A).  
Subsequently, examining the effects of intra-aNASh THC, ANOVA on time (s) spent in 
the closed arms revealed a main effect of treatment (F(5,40) = 12.535, p < .001). Post-hoc tests 
revealed that rats receiving intra-aNASh THC (100 ng/ 0.5 µg; n = 8) spent significantly less 
time in the closed arms compared to vehicle (n = 7; p = .002) and rats receiving intra-pNASh 
THC (100 ng/ 0.5 µg) + SC-79 (10 µM/ 0.5 µg; n = 7; p < .001; Figure 4.7B). Next, ANOVA 
testing on time (s) spent in the open arms following infusions into the aNASH, revealed a main 
effect of treatment (F(5,40) = 6.535, p = .006). Post-hoc tests revealed that rats receiving intra-
aNASh THC (100 ng/ 0.5 µg) + SB216763 (300 ng/ 0.5 µg; n = 8) spent significantly more time 
in the open arms compared to vehicle (n = 7; p = .004; Figure 4.7B). Taken together, these data 
indicate that intra-pNASh THC is anxiogenic on the EPM and the anxiogenic effect can be 
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reversed by GSKII blockade. Additionally, intra-aNASh THC is anxiolytic, an effect that is 
enhanced by AKT activation. 
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Figure 4.7 Effects of intra-NASh THC on anxiety in the elevated plus maze. A, Intra-pNASh 
THC decreases the amount of open arm time and increases the amount of closed arm time, which 
are both restored by co-administration of the GSK3 blocker SB216763 * = p < .05 compared to 
vehicle, ✟ = p < .05 compared to THC. B, Intra-aNASh THC increases the amount of open arm 
and decreases the amount of closed arm time, when co-administered with the Akt 
phosphorylation promoter SC-79, the anxiolytic effect is increased further * = p < .05 compared 
to vehicle, ✟ = p < .05 compared to THC. 
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4.4 DISCUSSION 
The nucleus accumbens serves as a critical point of integration in the mesolimbic circuitry for 
associative memory formation, cognitive and affective information processing. Previous 
evidence has demonstrated that THC strongly modulates signalling from regions that input the 
NAc, most notably the VTA (Cheer, 2004; Morra, Glick, & Cheer, 2010; Morra, Glick, & Cheer, 
2012; Oleson & Cheer, 2012), and that intra-NAc THC modulates mesolimbic signalling and 
NAc neuronal activity states (Cheer, 2004; Fitoussi et al., 2018; Morra et al., 2012; Oleson & 
Cheer, 2012). The NAc is also critically involved in the processing of fear-related associative 
memory and sensorimotor cognitive filtering (PPI) (Fadok et al., 2010; Iordanova, Westbrook, & 
Killcross, 2006). Nevertheless, the precise molecular and neuroanatomical mechanisms by which 
THC can produce dissociable effects within the ventral striatum on emotional memory formation 
and sensory integration have not been previously identified.  
 
In the present study, we demonstrate that THC produces anatomically dissociable, bivalent 
effects on associative memory processing, anxiety, object memory, and sensorimotor gating via 
dissociable molecular signalling pathways. First, targeting a battery of molecular biomarkers in 
the anterior vs. posterior NASh sub-regions, we found that THC in the pNASh selectively 
decreases phosphorylation of GSK3 and decreases expression levels of -catenin. In contrast, 
infusions of THC into the aNASh selectively decreases phosphorylated AktSer473 and 
phosphorylated mTOR expression levels. Together, these findings are the first demonstration for 
regionally selective modulation of these specific pathways within discrete NASh sub-regions and 
reveal new insights into how THC can produce localized effects on these signaling pathways 
within a common neural region. 
 
Behaviourally, we report that intra-pNASh infusions of THC produced GSK3 dependent 
potentiation of fear memory salience; induced anxiogenic effects and impaired PPI and PPF. In 
addition, pNASh THC exposure induced object recognition memory deficits. In contrast, intra-
aNASh THC blocked the encoding of normally supra-threshold associative fear memory and 
produced anxiolytic effects. When THC was co-administered with an Akt activator, the 
formation of associative fear memory was restored, time in the open arms during EPM increased 
above the levels of THC alone, PPF was impaired and object recognition memory was reduced. 
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Together, these data demonstrate the functional importance of the Wnt and mTOR pathways 
underlying regionally selective affective and cognitive impairments induced by THC in the 
anterior vs. posterior NASh subregions. 
 
At the molecular level, we and others have previously identified the roles of the Wnt and mTOR 
pathways in the functional effects of THC. For example, chronic or acute THC exposure 
profoundly alters phosphorylation and expression levels of  GSK3, Akt, mTOR, p70S6K, in the 
prefrontal cortex (Renard et al., 2016; Renard, Rosen, et al., 2017; Renard, Szkudlarek, et al., 
2017). In addition, mesolimbic Wnt signalling is critical for the processing of fear, anxiety and 
memory processing (Alimohamad, Rajakumar, Seah, & Rushlow, 2005; Cuesta et al., 2017; 
Korem et al., 2017; Maguschak & Ressler, 2011; Proto et al., 2017; Xu et al., 2011; Xu et al., 
2015). More specifically, Wnt was previously demonstrated to be necessary for the consolidation 
of fear memory in the hippocampus (Xu et al., 2015). Moreover, downregulating -catenin in the 
NAc was previously shown to impair extinction learning (Korem et al., 2017), indicating a 
critical role for this protein in striatal-mediated learning and memory processing. Additionally, a 
previous study demonstrated that infusions of atypical antipsychotics, cause increased GSK3 
phosphorylation and therefore a decrease in GSK3 activity (Alimohamad et al., 2005; Li, 
Rosborough, Friedman, Zhu, & Roth, 2007). In the present study, we found that infusions of 
THC into the pNASh produced several pathological effects, including impairments in PPI/PPF 
and increased anxiety, concomitant with decreased phosphorylation of GSK3. Together, these 
findings suggest that both the psychotomimetic effects and potentiation of fear memory 
formation induced by THC are regulated by local changes in canonical Wnt and -catenin 
signalling in the pNASh.  
 
The mTOR pathway has similarly been implicated in the processing of associative fear memory 
(Gafford et al., 2013; Jarome et al., 2018; Jobim et al., 2012; Puighermanal et al., 2013). For 
example, central administration of THC increased phosphorylation of Akt through a CB1 
receptor-dependent mechanism (Ozaita, Puighermanal, & Maldonado, 2007) and the effects of 
THC on memory formation in the hippocampus are modulated by mTOR signalling. While THC 
changes the activity of many distinct signalling molecules, the results of the present study 
provide a novel dissociation of separate localized signalling cascades within the NASh that show 
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clear and distinct patterns of activity following localized THC exposure. Future studies are 
required to further characterize the effects of intra-NASh THC on other signaling pathways in 
the Wnt interactome in order to fully elucidate these localized, THC-mediated signaling 
sequelae. 
 
Given the established effects of THC on disrupting sensorimotor gating and cognitive filtering 
(Renard et al., 2017), we next evaluated how intra-NASh infusions might influence PPI and PPF. 
Many previous studies have demonstrated that patients with schizophrenia have impairments in 
sensorimotor gating and therefore decreased PPF and PPI (Swerdlow et al., 2018; Wynn et al., 
2004). Indeed, deficits in PPI and PPF are established endophenotypes found in individuals 
considered to be at high risk of full-onset psychosis, and this risk is increased with exposure to 
cannabis (Winton-Brown et al., 2015). Whereas PPI abnormalities are considered to reflect 
deficits in sensory filtering, PPF deficits likely reflect deficits in sustained attention, both of 
which are cardinal cognitive endophenotypes associated with schizophrenia and other 
neuropsychiatric disorders. Thus, PPI deficits can be restored to normal levels by treatment with 
atypical anti-psychotics (Wynn et al., 2007). PPI is also impaired by THC in animal models 
(Malone & Taylor, 2006), and can be restored by co-administration of anti-psychotics (Nagai et 
al., 2006). Consistent with the present study, GSK3 has been implicated as an important 
molecular substrate necessary for normal PPI behaviours (Kapfhamer et al., 2010). Additionally, 
previous research has identified the NAc as an important neural region for PPI processing (Mohr, 
von Ameln-Mayerhofer, & Fendt, 2009). The results of the present study demonstrate that by 
increasing the phosphorylation state of the Wnt signalling pathway, consistent with a pro-
psychotic mechanism, intra-pNASh THC can impair both PPI and PPF, selectively in the 
posterior NASh. 
 
Consistent with the present study, previous research has demonstrated the importance of the NA 
for object memory (Nelson, Thur, Marsden, & Cassaday, 2010; Sargolini, Roullet, Oliverio, & 
Mele, 2003). For example, microinfusions of a NMDA antagonist into the NAc impaired object 
recognition memory (Sargolini et al., 2003). NMDA receptors are also known to regulate GSK3 
phosphorylation (De Sarno, Bijur, Zmijewska, Li, & Jope, 2006) which suggests a potential 
common mechanism for impairing object recognition memory with intra-pNASh microinfusions 
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of THC. Interestingly, we showed that activating the phosphorylation of Akt caused intra-aNASh 
to more closely resemble the effects of intra-pNASh, which is consistent with what we know 
about the substantial interactions between the GSK3 and mTOR pathways (Shi et al., 2014) 
within the Wnt interactome. Previous studies have also demonstrated that i.p. injections of THC 
impairs object recognition memory (Kasten et al., 2017) but none have examined the exact role 
the NASh plays in the process. The present study demonstrated that GSK3 signalling in the 
pNASh is involved in THC mediated impairment of object recognition memory. 
 
Considerable controversy exists, however, in the literature surrounding CB1 agonists and anxiety. 
While some studies have demonstrated anxiogenic effects (Genn, Tucci, Marco, Viveros, & File, 
2004; Schramm-Sapyta et al., 2007), others have shown anxiolytic effects (Berrendero & 
Maldonado, 2002). More recent studies, however, have suggested that the division between the 
seemingly opposing effects of THC on anxiety is primarily dose-dependent (Childs et al., 2017; 
Tiziana Rubino et al., 2007) including within the mesolimbic system (Rubino, Guidali, et al., 
2008). As THC dose increases, the effect of THC generally switches from anxiolytic to 
anxiogenic. The present study is the first to suggest that there are anatomically distinct processes 
within the anterior vs. posterior NASh regions mediated by separate molecular pathways that can 
influence the behavioural effects of THC in this affective domain.  
 
Consistent with our results showing selective down-regulation of GSK3 phosphorylation states 
in the posterior NASh (and hence, increased local levels of active GSK3), previous research has 
indicated that hyperactive GSK3 activity levels can produce anxiety (Mines, Yuskaitis, King, 
Beurel, & Jope, 2010; Qiao et al., 2018). Interestingly, the anxiolytic effect of intra-aNASh THC 
was not sensitive to an increase in Akt activity but this is consistent with some previous research 
indicating that the anxiolytic effect of THC is not sensitive to mTOR signalling (Puighermanal et 
al., 2013). Future research should attempt to elucidate the mechanism behind intra-aNASh THC 
anxiolysis and examine if increasing the dose of centrally administered THC increases the 
likelihood of stimulating the pNASh vs the aNASh. 
 
In summary, the results of the present study provide several novel mechanisms for how THC 
differentially modulates CB1 signalling pathways and bivalent effects on fear memory, object 
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recognition memory, anxiety, and sensorimotor gating. The present findings provide crucial new 
information for understanding the underlying molecular mechanisms of THC in anatomically 
distinct regions of the NASh and how they may underlie both the affective and cognitive side-
effects of cannabis exposure. 
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Characterizing both the effects of cannabis exposure represents one of the most complex 
challenges facing the neuropsychiatric research community. Given the overwhelming 
phytochemical complexity of cannabis, there is an urgent need to fully characterize the unique 
and sometimes opposing neurophysiological properties of these independent plant constituents. 
Currently, THC and CBD represent the best characterized of these phytocannabinoids in terms of 
their underlying pharmacological properties as well as their distinct and dissociable effects on 
various neuropsychiatric phenomena.  
 
The objectives of my thesis project were to characterize the neuronal, molecular, behavioural and 
pharmacological mechanisms responsible for the effects of THC and CBD, directly within the 
mammalian nucleus accumbens and associated mesolimbic regions such as the VTA. To achieve 
these research objectives, I have used an integrative combination of molecular protein signal 
analyses, behavioural pharmacological assays and in vivo neuronal electrophysiology targeting 
anatomically distinct sub-regions of the mammalian nucleus accumbens, with a special focus on 
the shell division of this structure. The combined results of my thesis projects have yielded a 
series of new insights and discoveries into the underlying neuronal, molecular and 
pharmacological effects of both THC and CBD, within distinct neuroanatomical sub-regions of 
the mammalian ventral striatum.  
 
5.1  Cannabidiol modulates fear memory formation through interactions 
with serotonergic transmission in the nucleus accumbens shell and 
modulation of ventral tegmental area neuronal activity 
 
In light of previous evidence of the therapeutic potential of CBD to treat anxiety (Bergamaschi et 
al., 2011; Crippa et al., 2011), schizophrenia (Leweke et al., 2012; Schubart et al., 2014; Zuardi, 
Crippa, Hallak, Moreira, & Guimaraes, 2006) and PTSD (Blessing, Steenkamp, Manzanares, & 
Marmar, 2015) and the role the mesolimbic circuit plays in psychiatric conditions, we first 
sought to examine the influence of CBD on mesolimbic neuronal function (Chapter 2). Previous 
research has also indicated that systemic administration of CBD enhanced fear memory 
extinction in humans (Das et al., 2013) and blocks the reconsolidation of fear memory in an 
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animal model (Stern, Gazarini, Takahashi, Guimarães, & Bertoglio, 2012). Given previous 
evidence demonstrating the importance of the NAc in fear memory processing (Fadok, Darvas, 
Dickerson, & Palmiter, 2010), we selected this brain region for our first studies. 
 
We found that microinfusions of CBD into the NASh during fear memory formation reduced 
subsequent freezing behaviour when presented with an odour that had been previously paired 
with a footshock. The formation of an associative fear memory was restored when CBD was co-
administered with the 5-HT1A antagonist NAD 299 but not the broad-spectrum dopamine 
antagonist -flu or the CB1R antagonist rimonabant. Furthermore, we tested the sensitivity of the 
rats to footshock following intra-NASh infusions of CBD compared to vehicle and found no 
difference. Taken together, these data indicate that CBD reduces the formation of associative 
fear memory formation directly in the NAc through activity on the 5-HT1A receptor, but 
independently of DAergic receptor transmission via the D1/D2 subtypes. Next, we sought to 
determine the underlying cellular activity responsible for these behavioural effects. Using in vivo 
electrophysiological techniques to record VTA neurons, we determined that intra-NASh CBD 
infusions decreased both firing and bursting rate of VTA DA neurons and concomitantly 
increased the activity of a subgroup of non-DA, presumptive GABAergic neurons. Finally, to 
ensure the change in activity of the VTA neurons and the behaviour were not epiphenomena, we 
performed a pharmacological disconnection study by simultaneously infusing CBD into the 
NASh and GABAA/GABAB blockers into the VTA in contralateral brain hemispheres. We found 
that while the GABA blockers had no effect on their own, they restored the formation of 
associative fear memory when co-administered with intra-NASh CBD. Thus, this evidence 
demonstrated the importance of NASh→VTA projections targeting GABAergic receptor 
substrates directly in the VTA, for the functional effects of intra-NASh CBD. Therefore, we 
demonstrated for the first time that CBD blocks the formation of associative fear memory by 
modulating the NASh/VTA circuitry through a 5-HT1A dependent mechanism directly in the 
NASh.  
 
Our results suggested that the neuroanatomical substrate responsible for the effects of CBD on 
the consolidation of fear memory are likely due to a direct modulation of the NASh/VTA circuit. 
More importantly, our findings provided further evidence for the effects of CBD on serotonergic 
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5-HT1A receptor signalling and indicate that despite producing its actions within the NASh, CBD 
can modulate fear-related behaviours independently of actions directly on DA D1/D2R receptor 
substrates. Together, the findings reported in Chapter 2 identify CBD as a potential therapeutic 
option for anxiety-related disorders. Indeed, there is now growing evidence that CBD possesses 
anxiolytic properties (Almeida et al., 2013; Blessing et al., 2015; Crippa et al., 2011). Our 
findings characterize a highly localized neuroanatomical locus wherein CBD might serve as an 
anxiolytic compound and provides a specific functional mechanism (reduction of DAergic 
activity in the mesolimbic pathway) by which CBD may produce these effects. In addition, given 
our findings that CBD strongly dampens the activity of mesolimbic DAergic states (consistent 
with previous studies in our lab (Renard et al., 2016)), these findings have important implications 
for CBD as a potential treatment for addiction-related behaviours. Indeed, virtually all drugs of 
abuse directly or indirectly activate the mesolimbic DA system (Volkow, Fowler, Wang, 
Swanson, & Telang, 2007; Young, Gobrogge, & Wang, 2011). The ability of CBD to inhibit 
DAergic activity states in the VTA suggests potential anti-addictive effects of CBD. Indeed, 
there is already existing evidence suggesting that CBD may serve as an effective inhibitor of 
opioid-related addiction phenomena (Hurd, 2017). 
 
5.2  THC Regulates Reward and Aversion Processing via Dissociable 
Opioid Receptor Substrates and Neuronal and Oscillatory Modulation 
in Distinct Striatal Sub-Regions 
 
In Chapter 3, I described a series of integrative experiments aimed at precisely characterizing the 
neuroanatomical loci of THC’s bivalent effects on reward and aversion-related behavioural 
processing. While it is well-established that THC can produce both reward and aversion effects, 
until now, the neurobiological mechanisms behind these bivalent effects have not been 
characterized. The NAc can be subdivided into the core (NACo) and shell (NASh) sub-regions. 
In terms of neuropsychiatric pathology, considerable evidence implicates a more critical role for 
the NASh, particularly in terms of functionally important connections with VTA-related DAergic 
transmission (Yang et al., 2018). However, within the NASh itself, emerging evidence points to 
important differences between the anterior and posterior poles of this sub-region. For example, 
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there are functional differences in terms of affective processing between the anterior and 
posterior NASh regions. The anterior region being critical for the processing of hedonic, reward-
related information, both for drug-related and natural associative reward stimuli; and the 
posterior NASh being critical for the processing of aversion-related affective information (Castro 
et al, 2016; Castro and Berridge, 2014; Mahler et al, 2007; Reynolds and Berridge, 2002; Smith 
and Berridge, 2007). Nevertheless, the underlying molecular mechanisms within the NASh 
responsible for modulating aversive, fear-related associative memory formation and cognitive 
function have not been characterized, particularly in relation to the potential involvement of the 
endocannabinoid system and the potential influence of THC within these accumbal sub-regions. 
  
Substantial amounts of clinical and pre-clinical research have demonstrated that functional 
anatomical divisions exist within the NAc. For example, beyond the divisions between the NASh 
and the NACo sub-regions, the anterior and posterior NASh are anatomically and functionally 
distinct. Previous studies have demonstrated the existence of a “hedonic hotspot” at the anterior 
pole of the NASh associated with a localized concentration of MORs and a corresponding 
paucity of KORs (Arvidsson et al., 1995; Castro & Berridge, 2014; Peciña & Berridge, 2000). 
Furthermore, previous evidence indicates a strong interaction between the endocannabinoid 
system and the opioid system (Ahmad & Laviolette, 2017; Mascia et al., 1999; Pickel et al., 
2004; Skelly et al., 2010). For example, rewarding effects associated with low doses of THC 
were absent in MOR knockout mice and aversion to high doses of THC was absent in KOR 
knockout mice (Ghozland et al., 2002). Therefore, we hypothesized that the rewarding effects of 
THC were due to activation of MORs in the aNASh and that the aversive effects of THC were 
due to activation of KORs in the pNASh. 
 
Consistent with this general hypothesis, we found that intra-aNASh microinfusions of THC 
produced strong conditioned reward effects in a CPP procedure through a MOR dependent 
mechanism. In contrast, intra-pNASh microinfusions of THC produced aversion through a KOR 
dependent mechanism. Additionally, intra-aNASh THC, but not intra-pNASh THC, potentiated 
reward to a sub-threshold dose of morphine. We also found that intra-pNASh, but not intra-
aNASH THC, reduced social motivation and social recognition. Previous studies have 
demonstrated the importance of the anterior/ posterior division in the NASh in reward processes 
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through stimulation of the endocannabinoid system and endogenous opioid receptors (Castro et 
al., 2016; Mahler et al., 2007). The data presented in chapter 3, however, demonstrates for the 
first time the significance of the division in reward from drug of abuse. 
 
The powerful motivational properties of drugs of abuse are what encourages repeated and 
compulsive use. Understanding the mechanisms behind drug-related reward effects is important 
for developing effective treatments for addiction. The changing attitudes towards the recreational 
use of cannabis also necessitates the investigation of THC reward specifically to insure proper 
policies of harm reduction. Like all drugs of abuse, THC effects DA release (Bossong et al., 
2015; Fitoussi, Zunder, Han, & Laviolette, 2018; Oleson & Cheer, 2012), and cannabinoid 
signaling plays a vital role in controlling DA release following the abuse of other rewarding 
substances (Cheer et al., 2007). Fully elucidating the role of cannabinoid signaling in producing 
reward, will further our understanding of the general mechanisms of addiction as well as the 
effects specific to cannabis abuse and dependence. Additionally, in the wake of legalization, 
cannabis is increasingly viewed as a harmless drug, but it can still produce numerous negative 
acute and long-term effects. Rates of cannabis use are likely to continue to increase and a proper 
understanding of the mechanisms behind some of the negative effects will help to minimize 
them.  
 
For example, many cannabis users report feelings of panic, paranoia and dysphoria following 
THC exposure (Freeman et al., 2015; Murray, Morrison, Henquet, & Di Forti, 2007). Our results 
suggest that the source of many of the negative effects of cannabis involve stimulation of the 
pNASH by THC. The respective sensitivities of the aNASh and pNASh to THC administration 
could be the source of the substantial variation in experience between individuals following 
cannabis consumption. The data presented in Chapter 3 could direct a new area of inquiry in 
human research to understand the biphasic effects of cannabis use on these psychotropic side-
effects. 
 
Next, to examine the functional mechanisms underlying these behaviours, we performed in vivo 
electrophysiological recordings within these anatomically distinct NASh sub-regions. We 
simultaneously recorded single-unit activity of MSNs and LFP. We discovered that ICV 
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infusions of THC strongly reduced the activity of aNASh MSNs but increased their activity 
states within the pNASh. The activity of striatal MSNs has been demonstrated to be vital for 
mediating motivation and learning in both animal and human models (Soares-Cunha, Coimbra, 
Sousa, & Rodrigues, 2016). Previous studies have suggested that the activity of MSNs can be 
subdivided into the direct pathway, which controls reward, mediated by D1R expressing neurons 
that input directly into the basal ganglia, and the indirect pathways which controls aversion and 
is mediated by D2R expressing neurons that input into the ventral pallidum. Recently, however, 
this model has been disputed as overly-simplistic and that the distinct pathways do not solely 
mediate opposing processes (Kupchik et al., 2015; Soares-Cunha, Coimbra, David-Pereira, et al., 
2016; Soares-Cunha, Coimbra, Sousa, & Rodrigues, 2016). The electrophysiological results 
presented in Chapter 3 provide further evidence that the role the NA plays in both reward and 
aversion cannot be distinctly parceled into the direct and indirect pathways. Further study is 
needed to fully elucidate the complex interplay of mechanisms that underlie the role of the NAc 
in motivation.   
 
Finally, we found that ICV infusions of THC caused an increase in the power of high-frequency 
gamma oscillations when recording in the aNASh but a decrease in the power of high-frequency 
gamma oscillations when recording in the pNASh. Gamma oscillations are altered by THC 
administration in human models (Cortes-Briones et al., 2015) and are associated with the 
psychotomimetic effects of THC (Nottage et al., 2015). Deficits in gamma oscillations are also 
common in schizophrenia and associated with many of the cognitive problems present in the 
disorder (McNally, McCarley, & Brown, 2013; Sun et al., 2011; Uhlhaas & Singer, 2010; Woo, 
Spencer, & McCarley, 2010). The association with schizophrenia and some of the negative 
effects of THC suggest that the changes we observed to gamma oscillations in the pNASh, may 
be responsible for some of the pro-psychotic effects of THC. Additionally, changes in gamma 
oscillations have been observed during reward processing in both rat (van der Meer & Redish, 
2009) and human models (Cohen et al., 2009). Methamphetamine induced increases in high-
frequency gamma oscillations in the nucleus accumbens are cannabinoid-receptor dependent 
(Morra et al., 2012), thus implicating gamma activity in the NAc in the rewarding states induced 
by drugs of abuse. In light of the previous research, our results demonstrating that THC increases 
the power of high-frequency gamma oscillations in the aNASh further demonstrate the 
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importance of both gamma oscillations of cannabinoid signaling to rewarding states created by 
drugs of abuse. Our results, however, suggest that the positive motivational states associated by 
the induction of high-frequency gamma oscillations can be attributed specifically to the aNASH. 
Overall, our results suggest that the seemingly contradictory effects of THC on appetitive 
processing are due to differential stimulation of distinct areas within the NASh. We have 
demonstrated that, for the first time, the effects of a drug of abuse on reward is rooted in the 
functional difference within the NASh. 
 
5.3  9-tetrahydrocannabinol (THC) Regulates Memory, Anxiety and 
Sensorimotor Gating via Dissociable Modulation of the Wnt and 
mTOR Signaling Pathways in Anatomically Distinct Nucleus 
Accumbens Shell Sub-Regions 
 
THC is well known to cause both relaxation and paranoia (Freeman et al., 2015; Rubino et al., 
2007). However, the anatomical and molecular mechanisms underlying these seemingly 
contradictory psychotropic effects remain unclear. Given our results detailed in Chapter 2, 
demonstrating that CBD could block the consolidation of fear memory formation by acting in the 
NASh and our results detailed in Chapter 3, demonstrating that the biphasic effects of THC on 
appetitive processing is due to dissociable and anatomically distinct processes within the NASh, 
we next sought to examine if the effects of THC on fear, memory, anxiety and sensorimotor 
gating are also rooted in localized differences with the NASh, via differential modulation of 
neuropsychiatric-related molecular signaling pathways.  
 
The cannabinoid system has been heavily implicated in the processing of emotionally salient 
stimuli and memory, including fear and anxiety. CB1 receptors, are expressed ubiquitously 
throughout the NAc and previous studies have demonstrated that CB1 signalling in the NAc is 
involved in a variety of affective and motivated behaviours, including food intake, addiction, 
stress and fear processing (Deshmukh & Sharma, 2012; Kuhnert, Meyer, & Koch, 2013; Li et al., 
2018; Papilloud, Guillot de Suduiraut, Zanoletti, Grosse, & Sandi, 2018; Pedroza-Llinás et al., 
2013; Wang et al., 2010). For example, peripubertal stress increased gene expression for CB1 
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within the NASh, suggesting the involvement of the ECS in regulating stress response (Papilloud 
et al., 2018). Anandamide (AEA), one of the primary endocannabinoids and a CB1 agonist, has 
been demonstrated to have biphasic effects on anxiety in the prefrontal cortex, producing both 
anxiogenic and anxiolytic effects (Rubino et al., 2008), suggesting that the eCB system plays a 
role in the balance of anxiety. Additionally, direct infusion of a selective CB1 agonist directly 
into the pNASH induced anxiogenesis in the EPM (Kochenborger et al., 2014). Thus, the 
apparent balancing role that the NAc eCB system plays in the modulation of affective 
information processing may suggest that exogenous cannabinoids, such as THC, may similarly 
produce both anxiogenic and anxiolytic effects. The exact molecular mechanisms behind how 
THC modulates anxiety and memory, however, have never been fully investigated. 
 
Previous work in our lab has established that THC alters the levels of many molecular signaling 
proteins associated with psychosis and mood disorders (Renard et al., 2017). Previous evidence 
has also implicated Wnt signaling pathways within the mesolimbic system in the consolidation 
of fear memory (Maguschak & Ressler, 2011) and extinction (Korem, Lange, Hillard, & Akirav, 
2017). Additionally, mTOR signaling has been implicated in the formation and reconsolidation 
of fear memory (Jobim et al., 2012), cannabinoid-mediated modulation of memory 
(Puighermanal et al., 2009), and the anxiogenic, but not anxiolytic effects, of THC 
(Puighermanal et al., 2013). Therefore, targeting these specific molecular biomarkers in the 
accumbens, we sought to examine if the effects of THC on fear-related memory formation, 
anxiety and cognition, were mediated by differential modulation of these molecular signaling 
pathways in anatomically localized NASh subregions. 
 
First, we found that, infusions of THC into the aNASh selectively decreased the phosphorylation 
of Akt at ser473, but not total Akt or phosphorylated Thr308 Akt, and decreased phosphorylated 
mTOR, but not total mTOR expression levels. In contrast, we found that infusions of THC into 
the pNASh decreased phosphorylated, but not total, GSK3 expression levels and increased 
expression levels of -catenin. Thus, these findings revealed novel and double-dissociable 
effects of THC within localized NASh sub-regions on several well-established molecular 
biomarkers associated with neuropsychiatric disorders.  At the behavioural level, we found that 
infusions of THC into the aNASh blocked the formation of associative fear memory to a supra-
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threshold footshock conditioning stimulus. However, this effect was reversed through 
pharmacological activation of Akt with SC-79. Conversely, we found that infusions of THC into 
the pNASh, potentiated the formation of associative fear formation to a sub-threshold footshock 
through a GSK3-dependent mechanism. Next, given previous evidence implicating THC and 
Wnt signaling in psychosis (Alimohamad, Rajakumar, Seah, & Rushlow, 2005; Renard et al., 
2017), and previous research demonstrating that a major behavioural hallmark of schizophrenia 
is a deficit in sensorimotor gating as assessed by a disruption in PPI (Braff & Geyer, 1990; 
Takahashi et al., 2008), we tested the effects of intra-NASh infusions of THC on PPI and PPF. 
Intra-pNASh, but not aNASh THC administration impaired both PPI and PPF. However, PPF 
was restored by blocking GSK3 activity. Subsequently, we tested the effects of intra-NASh THC 
on object recognition memory. We found that intra-pNASh THC decreased discrimination 
between the novel and familiar objects through a GSK3 dependent mechanism. Intra-aNASh 
THC, however, had no effect on discrimination unless it was co-administered with the Akt 
activator SC-79. Finally, we examined if the effects of THC on anxiety in the EPM were 
mediated by the same processes. We found that intra-pNASh infusions of THC decreased open-
arm time and increased closed-arm time through a GSK3 dependent mechanism. Intra-aNASh 
THC increased open-arm time and decreased closed-arm time, which was consistent with 
previous evidence (Puighermanal et al., 2013). However, the anxiolytic effect of THC was not 
sensitive to pharmacological modulation of Akt signaling by SC-79 co-administration.  
 
Striatal mTOR signaling is known to be importantly involved in learning and memory processes. 
For example, increases in phosphorylated mTOR levels were observed following skill learning in 
the striatum (Bergeron, Chagniel, Bureau, Massicotte, & Cyr, 2014). The decreased activity in 
the mTOR pathway following aNASh THC infusion is therefore the likely source of the fear 
memory deficits. Previous studies have demonstrated specific genetic factors in the mTOR 
pathway that link vulnerability to psychotic disorders following cannabis exposure. For example, 
the genetic risk of schizophrenia and psychosis in families can in part be determined by the 
sensitivity to the psychotomimetic effects of cannabis (Genetic Risk and Outcome of Psychosis 
(GROUP) Investigators, 2011). Interestingly, a specific single nucleotide polymorphism (SNP) 
on the AKT1 gene, which encodes the Akt protein, was associated with both psychotic disorder 
and sensitivity to the psychotomimetic effects of cannabis (Genetic Risk and Outcome of 
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Psychosis (GROUP) Investigators, 2011). Furthermore, a subsequent study also linked the same 
SNP to cannabis-induced long-term cognitive alterations in psychosis (Van Winkel & Genetic 
Risk and Outcome of Psychosis (GROUP) Investigators, 2011). Therefore, our results 
demonstrate remarkable translational consistency with the human genetics literature in terms of 
THC-induced modulation of the Akt signaling pathway.  
Previous studies have also demonstrated that mTOR is involved in the reward from drugs of 
abuse through the regulation of dopamine signaling (Liu, Li, Yu, Vickstrom, & Liu, 2017). 
mTOR signalling in the NASh is specifically involved in the regulation of dopamine 
concentration (Luo et al., 2016). These studies suggest that mTOR may therefore also be 
involved in the rewarding effects of aNASh THC infusions (Chapter 3). An important direction 
for future investigations would be to examine if THC may differentially affect the functional 
activity states of the anterior vs. posterior ventral striatum in patients with a family history of 
psychosis and/or how cannabis exposure might differentially modulate these subregions in the 
context of specific psychotropic side-effect profiles. 
 
The Wnt signaling pathway, and more specifically canonical Wnt, is heavily involved in the 
regulation of transcriptional factors and regulates stress and behavioural resilience (Dias et al., 
2014). The interaction between Wnt signaling and endocannabinoids in the NAc has also been 
demonstrated to regulate extinction learning (Korem et al., 2017). Dysregulation of this pathway 
is therefore likely to cause acute stress and is potentially responsible for the effects of THC 
infusion into the pNASh. Additionally, in vitro cell line studies have been conducted comparing 
neurons derived from human-induced pluripotent stem cells (hiPSC) from both schizophrenia 
and control lines. They determined that THC can induce similar changes to Wnt signaling as 
seen in the schizophrenia derived cells (Guennewig et al., 2018). Additionally, Min et al., (2011) 
identified a novel mechanism by which D2 receptors can recruit -catenin directly from the 
cytosol, bypassing GSK3 entirely, which may explain why both GSK3 and -catenin increased 
following pNASh infusions of THC. Given the predominance of the D2 indirect pathways in 
aversion processing and the data presented in chapter 3 demonstrating the role the pNASh plays 
in aversion, the changes in -catenin may be involved more in motivational states than memory 
or anxiety. Taken together with the previous genetic research, the data presented in chapter 4 
indicates that changes in molecular signaling in the NASh following THC infusions may also 
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underlie THC-induced short-term psychosis symptoms and increased risk for long-term 
psychotic disorders. Future studies should investigate if changes in pNASh activity induced by 
the effects of THC on Wnt signaling underlie the pro-psychotic effects of long-term cannabis 
use. 
 
Taken together, our results indicate the effects of intra-NASh THC on fear memory, anxiety, 
object recognition, and sensorimotor gating are mediated by dissociable changes in Wnt and 
mTOR signaling. Our results suggest that in addition to the biphasic effects of THC on appetitive 
processing being routed in functional differences between the pNASh and aNASh as 
demonstrated in Chapter 3, these functional differences are also the putative underlying 
mechanism associated with the multifaceted, biphasic effects of THC. 
 
5.4  Limitations 
The brain is a complex system of interacting networks, but the nature of any reductionist 
approach must be to examine neural regions and sub-divisions individually, before one can 
understand overall systems-level functions. As discussed in Chapter 1, even the mesolimbic 
pathway consists of multiple brain areas that establish a very complex circuit. The experiments 
presented here are focused on a subdivision of one area within that circuit, the nucleus 
accumbens shell. However, the NASh does not exist in a vacuum. To fully understand exactly 
how compounds in cannabis may alter this pathway, the other areas in this circuit must also be 
fully examined. For example, the BLA and mPFC have both been shown to be very important for 
the role that cannabinoid signaling has on fear and anxiety (Aliczki et al., 2016; Phan et al., 
2008; Ratano, Everitt, & Milton, 2014; Tan et al., 2011). Additionally, as discussed in Chapter 2, 
the endocannabinoid system interacts with many other neurotransmitter systems. While most of 
the present studies addressed the interactions with some other neurotransmitter systems, the 
endocannabinoid system heavily interacts with serotonin (Best & Regehr, 2008; Haj-Dahmane & 
Shen, 2011) and glutamate (Varma, Carlson, Ledent, & Alger, 2001) both of which have been 
heavily implicated in the normal function of the mesolimbic circuit. For example, glutamatergic 
signaling in the NASh is involved in both fear and desire and THC has been conclusively 
demonstrated to alter glutamate transmission (Colizzi, McGuire, Pertwee, & Bhattacharyya, 
2016). A complete view of the effects of THC on the mesolimbic reward pathway necessitates a 
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thorough investigation into the dynamics between different areas and between different 
neurotransmitter systems. 
 
Similarly, we only examined a fraction of the signaling proteins involved in the Wnt interactome. 
As discussed in Chapter 1, JNK is an important part of Wnt signaling and THC has previously 
been demonstrated to activate JNK (Rueda, Galve-Roperh, Haro, & Guzman, 2000). Other 
signaling proteins have also been implicated in the effects of THC on cognition. For example, 
extracellular signal related kinase (ERK) has been implicated in the effects of THC on memory 
(Derkinderen et al., 2003; Ruhl et al., 2014) and Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) has been implicated in the anxiolytic effects of low doses of THC (Rubino et al., 
2007). Additionally, we did not investigate the role of any signaling proteins on the effects of 
CBD, which might play a significant impact in its therapeutic potential (Renard et al., 2016). 
 
Cannabis use remains widespread and will likely increase with changing societal attitudes 
towards the safety and the normalization of cannabis use for recreational and therapeutic 
purposes (Pacula, Powell, Heaton, & Sevigny, 2015; Wen, Hockenberry, & Cummings, 2015).  
Undoubtedly, the specific phytochemical compounds within cannabis have tremendous potential, 
both for therapeutic applications and also in terms of increasing the risk of neuropsychiatric 
disorders. Of the phytocannabinoids described in this thesis, THC has primarily been implicated 
for its potential negative effects on mental health, whereas CBD appears to show tremendous 
promise as a treatment for schizophrenia and potentially anxiety-related disorders. The findings 
described in this thesis characterize the effects of THC and CBD within the NASh and have 
revealed numerous neurobiological mechanisms that appear to underlie many of the psychotropic 
effects of cannabis use. These data contribute to a growing body of both clinical and pre-clinical 
research on the diverse pharmacological effects of cannabinoids. In addition, this evidence 
highlights the important, yet divergent properties of these phytochemicals in terms of their 
potential positive and negative effects on mental health. 
 
5.5 Future Directions 
As previously discussed the mesocorticolimbic circuitry is highly interconnected. Extending the 
work outlined in this thesis to examine potential interactions with other limbic regions such as 
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the mPFC and BLA, would help further characterize the effects of cannabis compounds on 
cognition, memory and emotion. Indeed, considerable evidence from our laboratory has 
extensively characterized how cannabinoid CB1 receptor signaling within both the BLA and PFC 
can control emotional processing and memory formation (Ahmad & Laviolette, 2016; Ahmad et 
al., 2017; Tan et al., 2011; Tan, Ahmad, Loureiro, Zunder, & Laviolette, 2014). Examining 
specifically how THC and CBD may act within these neural regions would greatly expand our 
knowledge of how phytocannabinoid signaling across and within the mesocorticolimbic circuitry 
may differentially influence mental health related phenomena.  
 
As discussed previously in Chapter 4, due to time limitations, we were only able to test a subset 
of potentially dozens of specific signaling proteins involved in the effects of THC within the 
NASh. While we were able to reveal several novel and functional roles for GSK3, mTOR and 
Wnt signaling within these THC effect parameters, examining the potential roles of other 
signaling pathways on the effects of THC in the mesolimbic circuitry would provide a more 
detailed and precise characterization of the molecular mechanisms underlying the effects of 
THC. For example, JNK is involved in non-canonical Wnt signaling and previous research has 
demonstrated that THC activates JNK through stimulation of CB1Rs (Rueda et al., 2000). JNK 
activation in the NAc is also necessary for the consolidation of cocaine-associated reward 
memories (Ding et al., 2013) and cocaine-induced NAc plasticity (Dietz et al., 2012), which 
suggests that JNK activation might also be required for associative memories involving other 
drugs of abuse like THC. ERK has also been demonstrated to be substantially involved in the 
processing of reward in the NAc. Intra-NAc amphetamine CPP is dependent on ERK activation 
(Gerdjikov, Ross, & Beninger, 2004) and decreases in phosphorylated ERK in the NAc are 
associated with morphine administration (Rosas et al., 2016) and heroin seeking following cue 
presentation (Sun et al., 2015). CaMKII in the NA also plays an important role in changes 
associated with drugs of abuse. Inhibition of CaMKII in the NA blocks increased amphetamine 
consumption following sensitization (Loweth, Baker, Guptaa, Guillory, & Vezina, 2008) and 
blocks the reinstatement of morphine-seeking behavior (Liu, Zhang, Liu, & Yu, 2012).  
Additionally, as we did not evaluate the effects of CBD on any specific signaling proteins, future 
studies should examine if CBD may have similar and/or opposing effects on these related 
molecular signaling pathways. 
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Furthermore, in each of these studies, we only examined the effects of THC and CBD 
individually. Substantial amounts of previous research have indicated that THC and CBD alter 
the effects of one another. For example, THC/CBD co-administration demonstrates synergistic 
effects on behavior and pharmacokinetics (Hložek et al., 2017; Jacobs et al., 2016; Todd et al., 
2017). Given the increasing amounts of THC and decreasing amounts of CBD in many of the 
cannabis products currently consumed, it is important to understand how CBD may potentially 
alter the effects of THC and/or act synergistically, when they are administered together. 
 
An additional limitation to the present experiments concerns the complexity of memory 
formation and learning. For example, when we evaluated the effects of CBD and THC on fear 
memory formation, our drug administration procedures selectively targeted the memory 
acquisition (encoding) phase of the process. Thus, while our results show the powerful effects of 
CBD and THC on the acquisition of associative fear memory, memory formation and 
maintenance is a complex and multifaceted process that includes phases of consolidation, 
retrieval, reconsolidation and extinction. In order to fully characterize the potential risks of THC 
and/or the potential therapeutic effects of CBD, a more complete examination of memory 
processing is needed. Previous research has been dedicated to examining the effects of these 
compounds on other aspects of memory, such as recall and extinction, but the exact mechanisms 
behind those effects have not been fully explored. For example, studies examining how THC or 
CBD might modulate the consolidation, recall or extinction of associative fear memory or 
addiction-related memories, may provide important and useful insights into how they may more 
effectively be administered to clinical populations to target these neuropsychiatric symptom 
profiles. 
 
Lastly, to more directly compare the neurophysiological effects of THC and CBD on neuronal 
activity dynamics, recording cells in the VTA following intra-NASh THC infusions and 
conversely, recording the activity of MSNs in the NASh following CBD infusions could provide 
new insights into the differential effects of THC and CBD on mesolimbic neuronal function.  
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5.6 CONCLUSIONS 
Cannabis use remains widespread and will likely increase with changing societal attitudes 
towards the safety and the normalization of cannabis use for recreational and therapeutic 
purposes. Undoubtedly, the specific phytochemical compounds within cannabis have tremendous 
potential, both positive and negative, for therapeutic applications and in terms of increasing the 
risk of certain neuropsychiatric disorders. Of the phytocannabinoids examined in this thesis, 
THC has primarily been implicated for its potential negative effects on mental health, whereas 
CBD appears to demonstrate promise as a treatment for schizophrenia and potentially anxiety 
disorders and PTSD. Nevertheless, critical questions remain regarding the specific brain regions 
and precise molecular signaling mechanisms underlying these diverse effects. Remarkably, the 
data reported in this thesis underscores the incredible divergence of neurobiological and 
neuropsychiatric effects induced by two distinct phytochemicals located within the same plant. 
 
The findings described in this thesis have extensively characterized the effects of THC and CBD 
specifically within the NASh and distinct anatomical sub-regions therein.  Using integrative 
molecular, neuronal and behavioural testing, these studies have revealed numerous novel 
neurobiological mechanisms that appear to underlie many of the psychotropic effects of cannabis 
use. The data contained in this thesis will contributes to a growing body of both clinical and pre-
clinical research on the diverse pharmacological effects of cannabinoids. In addition, this 
evidence highlights the important, yet divergent properties of these phytochemicals in terms of 
their potential positive and negative effects on mental health and will hopefully help lay the 
foundation for future development and innovations in cannabinoid-based mental health 
pharmacotherapies. 
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